SB 1408: Tissue donation.
- Session Year: 2015-2016
- House: Senate
- Latest Version Date: 2016-05-27
(1)Existing law prohibits the transfer of any tissues, as defined, into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), human T lymphotropic virus (HTLV), and syphilis, except as provided. Existing law requires that all donors of sperm be screened and found nonreactive under the above provisions, except as provided. Existing law authorizes the transplantation of tissue from a donor who has not been tested for specified infectious diseases or, with the exception of HIV and HTLV, has been found reactive, if specified conditions are satisfied.
This bill would delete the exception of HIV from this provision. The bill would require a physician and surgeon performing the transplantation of an organ from an HIV-reactive donor to ensure that the recipient is also HIV reactive and complying with federal law, as specified.
(2)Under existing law, it is a felony for a person to donate blood, body organs or other tissue, or semen to a medical center or semen bank who knows that he or she has acquired immunodeficiency syndrome (AIDS) except if the person is a sperm donor who has been screened and found nonreactive under the above provisions. Under existing law, a person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, and any person who willfully exposes another person afflicted with the disease to someone else, is guilty of a misdemeanor, except as provided.
This bill would exempt those sperm donors and organ donors from those criminal provisions.
(3)Existing law authorizes the Medical Board of California and the California Board of Podiatric Medicine to take disciplinary action against a physician, surgeon, and other licensed or regulated individual who knowingly fails to protect patients by failing to follow infection control guidelines and risks transmission of blood-borne infectious diseases, as specified.
This bill would exempt the performance of an organ transplant, as authorized by this bill, from disciplinary action.
This bill would declare that it is to take effect immediately as an urgency statute.
(1)Existing law prohibits the transfer of any tissues, as defined, into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), human T lymphotropic virus (HTLV), and syphilis, except as provided. Existing law requires that all donors of sperm be screened and found nonreactive under the above provisions, except as provided. Existing law authorizes the transplantation of tissue from a donor who has not been tested for specified infectious diseases or, with the exception of HIV and HTLV, has been found reactive, if specified conditions are satisfied.
This bill would delete the exception of HIV from this provision. The bill would require a physician and surgeon performing the transplantation of an organ from an HIV-reactive donor to ensure that the recipient is also HIV reactive and complying with federal law, as specified.
(2)Under existing law, it is a felony for a person to donate blood, body organs or other tissue, or semen to a medical center or semen bank who knows that he or she has acquired immunodeficiency syndrome (AIDS) except if the person is a sperm donor who has been screened and found nonreactive under the above provisions. Under existing law, a person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, and any person who willfully exposes another person afflicted with the disease to someone else, is guilty of a misdemeanor, except as provided.
This bill would exempt those sperm donors and organ donors from those criminal provisions.
(3)Existing law authorizes the Medical Board of California and the California Board of Podiatric Medicine to take disciplinary action against a physician, surgeon, and other licensed or regulated individual who knowingly fails to protect patients by failing to follow infection control guidelines and risks transmission of blood-borne infectious diseases, as specified.
This bill would exempt the performance of an organ transplant, as authorized by this bill, from disciplinary action.
This bill would declare that it is to take effect immediately as an urgency statute.
(1)Existing law prohibits the transfer of any tissues, as defined, into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), human T lymphotropic virus (HTLV), and syphilis, except as provided. Existing law requires that all donors of sperm be screened and found nonreactive under the above provisions, except as provided. Existing law authorizes the transplantation of tissue from a donor who has not been tested for specified infectious diseases or, with the exception of HIV and HTLV, has been found reactive, if specified conditions are satisfied.
This bill would delete the exception of HIV from this provision. The bill would require a physician and surgeon performing the transplantation of an organ from an HIV-reactive donor to ensure that the recipient is also HIV reactive and complying with federal law, as specified.
(2)Under existing law, it is a felony for a person to donate blood, body organs or other tissue, or semen to a medical center or semen bank who knows that he or she has acquired immunodeficiency syndrome (AIDS) except if the person is a sperm donor who has been screened and found nonreactive under the above provisions. Under existing law, a person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, and any person who willfully exposes another person afflicted with the disease to someone else, is guilty of a misdemeanor, except as provided.
This bill would exempt those sperm donors and organ donors from those criminal provisions.
(3)Existing law authorizes the Medical Board of California and the California Board of Podiatric Medicine to take disciplinary action against a physician, surgeon, and other licensed or regulated individual who knowingly fails to protect patients by failing to follow infection control guidelines and risks transmission of blood-borne infectious diseases, as specified.
This bill would exempt the performance of an organ transplant, as authorized by this bill, from disciplinary action.
This bill would declare that it is to take effect immediately as an urgency statute.
(1)Existing law prohibits the transfer of any tissues, as defined, into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), human T lymphotropic virus (HTLV), and syphilis, except as provided. Existing law requires that all donors of sperm be screened and found nonreactive under the above provisions, except as provided. Existing law authorizes the transplantation of tissue from a donor who has not been tested for specified infectious diseases or, with the exception of HIV and HTLV, has been found reactive, if specified conditions are satisfied.
This bill would delete the exception of HIV from this provision. The bill would require a physician and surgeon performing the transplantation of tissue an organ from an HIV-reactive donor to ensure that the recipient is also HIV reactive and complying with federal law, as specified.
(2)Under existing law, it is a felony for a person to donate blood, body organs or other tissue, or semen to a medical center or semen bank who knows that he or she has acquired immunodeficiency syndrome (AIDS) except if the person is a sperm donor who has been screened and found nonreactive under the above provisions. Under existing law, a person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, and any person who willfully exposes another person afflicted with the disease to someone else, is guilty of a misdemeanor, except as provided.
This bill would exempt those sperm donors and tissue organ donors from those criminal provisions.
(3)Existing law authorizes the Medical Board of California and the California Board of Podiatric Medicine to take disciplinary action against a physician, surgeon, and other licensed or regulated individual who knowingly fails to protect patients by failing to follow infection control guidelines and risks transmission of blood-borne infectious diseases, as specified.
This bill would exempt the performance of an organ transplant, as authorized by this bill, from disciplinary action.
(1)Existing law prohibits the transfer of any tissues, as defined, into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), human T lymphotropic virus (HTLV), and syphilis, except as provided. Existing law requires that all donors of sperm be screened and found nonreactive under the above provisions, except as provided. Existing law authorizes the transplantation of tissue from a donor who has not been tested for specified infectious diseases or, with the exception of HIV and HTLV, has been found reactive, if specified conditions are satisfied.
This bill would delete the exception of HIV from this provision. The bill would require a physician and surgeon performing the transplantation of tissue from an HIV-reactive donor to ensure that the recipient is also HIV reactive and complying with federal law, as specified.
(2)Under existing law, it is a felony for a person to donate blood, body organs or other tissue, or semen to a medical center or semen bank who knows that he or she has acquired immunodeficiency syndrome (AIDS) except if the person is a sperm donor who has been screened and found nonreactive under the above provisions. Under existing law, a person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, and any person who willfully exposes another person afflicted with the disease to someone else, is guilty of a misdemeanor, except as provided.
This bill would exempt those sperm donors and tissue donors from those criminal provisions.
Existing
(1)Existing law prohibits the transfer of any tissues, as defined, into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), human T lymphotropic virus (HTLV), and syphilis, except as provided. Existing law requires that all donors of sperm be screened and found nonreactive under the above provisions, except as provided. Existing law authorizes the transplantation of tissue from a donor who has not been tested for specified infectious diseases or, with the exception of HIV and HTLV, has been found reactive, if specified conditions are satisfied.
This bill would delete the exception of HIV from this provision.
(2)Under existing law, it is a felony for a person to donate blood, body organs or other tissue, or semen to a medical center or semen bank who knows that he or she has acquired immunodeficiency syndrome (AIDS) except if the person is a sperm donor who has been screened and found nonreactive under the above provisions. Under existing law, a person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, and any person who willfully exposes another person afflicted with the disease to someone else, is guilty of a misdemeanor, except as provided.
This bill would exempt those sperm donors and tissue donors from those criminal provisions.
Existing law prohibits the transfer of any tissues, as defined, into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), human T lymphotrophic virus (HTLV), and syphilis, except as provided. Existing law requires that all donors of sperm be screened and found nonreactive under the above provisions, except as provided. Existing law authorizes the transplantation of tissue from a donor who has not been tested for specified infectious diseases or, with the exception of HIV and HTLV, has been found reactive, if specified conditions are satisfied.
This bill would delete the exception of HIV from this provision.
Existing law, until January 1, 2018, requires the State Department of Public Health to convene a workgroup to update the 2008 Guidelines for Alzheimers Disease Management in California to address changes in the health care system. Existing law requires the department to submit a report of the updates and recommendations from the working group to the Legislature on or before March 1, 2017.
This bill would make technical, nonsubstantive changes to these provisions.
Existing law, until January 1, 2018, requires the State Department of Public Health to convene a workgroup to update the 2008 Guidelines for Alzheimers Disease Management in California to address changes in the health care system. Existing law requires the department to submit a report of the updates and recommendations from the working group to the Legislature on or before March 1, 2017.
This bill would make technical, nonsubstantive changes to these provisions.
(a)The board and the California Board of Podiatric Medicine shall investigate and may take disciplinary action, including, but not limited to, revocation or suspension of licenses, against physicians and surgeons and all others licensed or regulated by the board, or by the California Board of Podiatric Medicine, whichever is applicable, who, except for good cause, knowingly fail to protect patients by failing to follow infection control guidelines of the applicable board, thereby risking transmission of blood-borne infectious diseases from the physician and surgeon or other health care provider licensed or regulated by the applicable board to patients, from patients, and from patient to physician and surgeon or other health care provider regulated by the applicable board. In so doing, the boards shall consider referencing the standards, regulations, and guidelines of the State Department of Health Services developed pursuant to Section 1250.11 of the Health and Safety Code and the standards, guidelines, and regulations pursuant to the California Occupational Safety and Health Act of 1973 (Part 1 (commencing with Section 6300), Division 5, Labor Code) for preventing the transmission of HIV, hepatitis B, and other blood-borne pathogens in health care settings. As necessary, the board and the California Board of Podiatric Medicine shall consult with the Board of Dental Examiners, the Board of Registered Nursing, and the Board of Vocational Nursing and Psychiatric Technicians, to encourage appropriate consistency in the implementation of this section.
(b)Subdivision (a) shall not apply to an organ transplant performed within the standard of care and in compliance with subdivision (d) of Section 1644.5 of the Health and Safety Code.
(c)The board shall seek to ensure that licentiates and others regulated by the board are informed of the responsibility of licentiates to follow infection control guidelines and of the most recent scientifically recognized safeguards for minimizing the transmission of blood-borne infectious diseases.
SEC. 2.Section 1621.5 of the Health and Safety Code is amended to read:1621.5.(a) It is a felony punishable by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code for two, four, or six years, for any person to donate blood or tissue, semen to any medical center or semen bank that receives semen for purposes of artificial insemination, or breast milk to any medical center or breast milk bank that receives breast milk for purposes of distribution, whether he or she is a paid or a volunteer donor, who knows that he or she has acquired immunodeficiency syndrome (AIDS), as diagnosed by a physician and surgeon, or who knows that he or she has tested reactive to HIV. This section shall not apply to any person who is mentally incompetent or who self-defers his or her blood at a blood bank or plasma center pursuant to subdivision (b) of Section 1603.3 or who donates his or her blood for purposes of an autologous donation.
(b) In a criminal investigation for a violation of this section, no person shall disclose the results of a blood test to detect the etiologic agent of AIDS or antibodies to that agent to any officer, employee, or agent of a state or local agency or department unless the test results are disclosed as otherwise required by law pursuant to any one of the following:
(1) A search warrant issued pursuant to Section 1524 of the Penal Code.
(2) A judicial subpoena or subpoena duces tecum issued and served in compliance with Chapter 2 (commencing with Section 1985) of Title 3 of Part 4 of the Code of Civil Procedure.
(3) An order of a court.
(c) For purposes of this section, blood means human whole blood and human whole blood derivatives, as defined for purposes of this chapter and includes blood components, as defined in subdivision (k) of Section 1603.1.
(d)For purposes of this section, tissue shall have the same meaning as defined in paragraph (1) of subdivision (c) of Section 1635.
SEC. 3.Section 1635 of the Health and Safety Code is amended to read:1635.(a)Donor means an individual, living or deceased, from whom tissue is removed.
(b)Person means an individual, corporation, business trust, estate trust, partnership, association, state or local government, or subdivision or agency thereof, or any other legal entity.
(c)(1)Tissue means a human cell, group of cells, including the cornea, sclera, or vitreous humor and other segments of, or the whole eye, bones, skin, arteries, sperm, blood, other fluids, and any other portion of a human body, but shall not include an organ when recovered for transplantation or research purposes.
(2)For purposes of paragraph (1), organ means a human kidney, liver, heart, lung, pancreas, intestine (including the esophagus, stomach, small or large intestine, or any portion of the gastrointestinal tract), or vascularized composite allograft, and associated blood vessels recovered from an organ donor during the recovery of the organ.
(d)Tissue bank means a place, establishment, or institution that collects, processes, stores, or distributes tissue for transplantation into human beings.
(e)Transplantation means the act or process of transferring tissue, including by ingestion, from a donor to the body of the donor or another human being.
(f)Department means the State Department of Public Health.
SEC. 4.Section 1635.1 of the Health and Safety Code is amended to read:1635.1.(a)Except as provided in subdivision (b), every tissue bank operating in California on or after July 1, 1992, shall have a current and valid tissue bank license issued or renewed by the department pursuant to Section 1639.2 or 1639.3.
(b)This chapter does not apply to any of the following:
(1)The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed pursuant to Chapter 4 (commencing with Section 1600) or any person exempt from licensure under that chapter.
(2)The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable.
(3)The collection of tissue by an individual physician and surgeon from his or her patient or the implantation of tissue by an individual physician and surgeon into his or her patient. This exemption shall not be interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter.
(4)The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus.
(5)The collection, processing, storage, or distribution by an organ procurement organization (OPO), as defined in Section 485.302 of Title 42 of the Code of Federal Regulations, if the OPO, at the time of collection, processing, storage, and distribution of the tissue, has been designated by the Secretary of Health and Human Services as an OPO, pursuant to Section 485.305 of Title 42 of the Code of Federal Regulations, and meets the requirements of Sections 485.304 and 485.306 of Title 42 of the Code of Federal Regulations, as applicable.
(6)The storage of prepackaged, freeze-dried bone by a general acute care hospital.
(7)The storage of freeze-dried bone and dermis by any licensed dentist practicing in a lawful practice setting, if the freeze-dried bone and dermis has been obtained from a licensed tissue bank, is stored in strict accordance with a kits package insert and any other manufacturer instructions and guidelines, and is used for the express purpose of implantation into a patient.
(8)The storage of a human cell, tissue, or cellular- or tissue-based product, as defined by the federal Food and Drug Administration, that is either a medical device approved pursuant to Section 510 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Secs. 360 and 360e) or that is a biologic product approved under Section 351 of the federal Public Health Service Act (42 U.S.C. Sec. 262) by a licensed physician or podiatrist acting within the scope and authority of his or her license and practicing in a lawful practice setting. The medical device or biologic product must have been obtained from a California licensed tissue bank, been stored in strict accordance with the devices or products package insert and any other manufacturer instructions, and used solely for the express purpose of direct implantation into or application on the practitioners own patient. In order to be eligible for the exemption in this paragraph, the entity or organization where the physician or podiatrist who is eligible for the exemption is practicing shall notify the department, in writing, that the practitioner is licensed and meets the requirements of this paragraph. The notification shall include all of the following:
(A)A list of all practitioners to whom the notice applies.
(B)Acknowledgment that each listed practitioner uses the medical device or biologic product in the scope and authority of his or her license and practice for the purposes of direct patient care as described in this paragraph.
(C)A statement that each listed practitioner agrees to strictly abide by the directions for storage in the devices or products package insert and any other manufacturer instructions and guidelines.
(D)Acknowledgment by each practitioner that the medical device or biologic product shall not be resold or distributed.
(9)The collection, processing, storage, or distribution of any organ, as defined in paragraph (2) of subdivision (c) of Section 1635, within a single general acute care hospital, as defined in subdivision (a) of Section 1250, operating a Medicare-approved transplant program.
SEC. 5.Section 1644.5 of the Health and Safety Code is amended to read:1644.5.(a)Except as provided in subdivision (c) or (d), no tissues shall be transferred into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive by laboratory tests for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), and syphilis. For tissues that are rich in viable leukocytes, the tissue shall be tested for evidence of infection with human T lymphotropic virus (HTLV) and found nonreactive. The department may adopt regulations requiring additional screening tests of donors of tissues when, in the opinion of the department, the action is necessary for the protection of the public, donors, or recipients.
(b)Notwithstanding subdivision (a), infectious disease screening of blood and blood products shall be carried out solely in accordance with Article 2 (commencing with Section 1602.5) of Chapter 4.
(c)All donors of sperm shall be screened and found nonreactive as required under subdivision (a), except in the following instances:
(1)A recipient of sperm, from a sperm donor known to the recipient, may waive a second or other repeat testing of that donor if the recipient is informed of the requirements for testing donors under this section and signs a written waiver.
(2)A recipient of sperm may consent to therapeutic insemination of sperm or use of sperm in other assisted reproductive technologies even if the sperm donor is found reactive for hepatitis B, hepatitis C, syphilis, HIV, or HTLV if the sperm donor is the spouse of, partner of, or designated donor for that recipient. The physician providing insemination or assisted reproductive technology services shall advise the donor and recipient of the potential medical risks associated with receiving sperm from a reactive donor. The donor and the recipient shall sign a document affirming that each comprehends the potential medical risks of using sperm from a reactive donor for the proposed procedure and that each consents to it. Copies of the document shall be placed in the medical records of the donor and the recipient.
(3)(A)Sperm whose donor has tested reactive for syphilis may be used for the purposes of insemination or assisted reproductive technology only after the donor has been treated for syphilis. Sperm whose donor has tested reactive for hepatitis B may be used for the purposes of insemination or assisted reproductive technology only after the recipient has been vaccinated against hepatitis B.
(B)(i)Sperm whose donor has tested reactive for HIV or HTLV may be used for the purposes of insemination or assisted reproductive technology for a recipient testing negative for HIV or HTLV only after the donors sperm has been effectively processed to minimize the infectiousness of the sperm for that specific donation and where informed and mutual consent has occurred.
(ii)The department shall adopt regulations regulating facilities that perform sperm processing, pursuant to this subparagraph, that prescribe standards for the handling and storage of sperm samples of carriers of HIV, HTLV, or any other virus as deemed appropriate by the department. The department may propose to adopt, as initial regulations, the recommendations made within the Guidelines for Reducing Risk of Viral Transmission During Fertility Treatment as published by the American Society for Reproductive Medicine. Notice of the departments proposed adoption of the regulations shall be posted on the departments Internet Web site for at least 45 days. Public comment shall be accepted by the department for at least 30 days after the conclusion of the 45-day posting period. If a member of the public requests a public hearing during the 30-day comment period, the hearing shall be held prior to the adoption of the regulations. If no member of the public requests a public hearing, the regulations shall be deemed adopted at the conclusion of the 30-day comment period. Comments received shall be considered prior to the adoption of the final initial regulations. The department may modify any guidance published by the American Society for Reproductive Medicine. Adoption of initial regulations by the department pursuant to this subdivision shall not be subject to the rulemaking requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code and written responses to public comments shall not be required. Updates to the regulations shall be adopted pursuant to the same process. Until the department adopts these regulations, facilities that perform sperm processing pursuant to this section shall follow facility and sperm processing guidelines for the reduction of viral transmission developed by the American Society for Reproductive Medicine. Nothing in this section shall prevent the department from monitoring and inspecting facilities that process sperm to ensure adherence to the regulations, or, until regulations are adopted, to the guidelines set forth by the American Society for Reproductive Medicine.
(iii)Prior to insemination or other assisted reproductive technology services, the physician providing the services shall inform the recipient of sperm from a spouse, partner, or designated donor who has tested reactive for HIV or HTLV of all of the following:
(I)That sperm processing may not eliminate all of the risks of HIV or HTLV transmission.
(II)That the sperm may be tested to determine whether or not it is reactive for HIV or HTLV.
(III)That the recipient must provide documentation to the physician providing insemination or assisted reproductive technology services prior to treatment that she has established an ongoing relationship with another physician to provide for her medical care during and after completion of fertility services.
(IV)The recommendations made within the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine regarding followup testing for HIV and HTLV after use of sperm from an HIV or HTLV reactive donor and have the recommendations regarding followup testing be documented in the recipients medical record.
(iv)The physician providing insemination or assisted reproductive technology services shall also verify, and document in the recipients medical record, that the donor of sperm who tests reactive for HIV or HTLV is under the care of a physician managing the HIV or HTLV.
(v)The physician providing insemination or assisted reproductive technology services shall recommend to the physician who will be providing ongoing care to the recipient recommended followup testing for HIV and HTLV according to the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine, which shall be documented in the recipients medical record.
(vi)If the recipient becomes HIV or HTLV positive, the physician assuming ongoing care of the recipient shall treat or provide information regarding referral to a physician who can provide ongoing treatment of the HIV or HTLV.
(4)A recipient of sperm donated by a sexually intimate partner of the recipient for reproductive use may waive a second or repeat testing of that donor if the recipient is informed of the donor testing requirements of this section and signs a written waiver. For purposes of this paragraph, sexually intimate partner of the recipient includes a known or designated donor to whose sperm the recipient has previously been exposed in a nonmedical setting in an attempt to conceive.
(d)Subdivision (a) shall not apply to the transplantation of tissue from a donor who has not been tested or, with the exception of HTLV, has been found reactive for the infectious diseases listed in subdivision (a) or for which the department has, by regulation, required additional screening tests, if all of the following conditions are satisfied:
(1)The physician and surgeon performing the transplantation has determined any one or more of the following:
(A)Without the transplantation the intended recipient will most likely die during the period of time necessary to obtain other tissue or to conduct the required tests.
(B)The intended recipient already is diagnosed with the infectious disease for which the donor has tested positive.
(C)The symptoms from the infectious disease for which the donor has tested positive will most likely not appear during the intended recipients likely lifespan after transplantation with the tissue or may be treated prophylactically if they do appear.
(2)The physician and surgeon performing the transplantation has ensured that an organ from an individual who has been found reactive for HIV may be transplanted only into an individual who satisfies both of the following:
(A)The individual has been found reactive for HIV before receiving the organ.
(B)The individual is either participating in clinical research approved by an institutional review board under the criteria, standards, and regulations described in subsections (a) and (b) of Section 274f-5 of Title 42 of the United States Code, or, if the United States Secretary of Health and Human Services determines under subsection (c) of Section 274f-5 of Title 42 of the United States Code that participation in this clinical research is no longer warranted as a requirement for transplants, the individual is receiving the transplant under the standards and regulations under subsection (c) of Section 274f-5 of Title 42 of the United States Code.
(3)Consent for the use of the tissue has been obtained from the recipient, if possible, or if not possible, from a member of the recipients family, or the recipients legal guardian. For purposes of this section, family shall mean spouse, adult son or daughter, either parent, adult brother or sister, or grandparent.
(e)The penalties prescribed in Sections 1621.5 and 120290 do not apply to a sperm donor covered under subdivision (c) or an organ donor who donates an organ for transplantation or research purposes.
(f)Human breast milk from donors who test reactive for agents of viral hepatitis (HBV and HCV), HTLV, HIV, or syphilis shall not be used for deposit into a milk bank for human ingestion in California.
SEC. 6.Section 120290 of the Health and Safety Code is amended to read:120290.(a)Except as provided in Section 120291 or in the case of the removal of an afflicted person in a manner the least dangerous to the public health, any person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, and any person who willfully exposes another person afflicted with the disease to someone else, is guilty of a misdemeanor.
(b)This section shall not apply to a person who donates an organ for transplantation or research purposes.
SEC. 7.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to provide for organ donations and transplants to occur at the earliest opportunity, it is necessary that this act take effect immediately.
(a)The board and the California Board of Podiatric Medicine shall investigate and may take disciplinary action, including, but not limited to, revocation or suspension of licenses, against physicians and surgeons and all others licensed or regulated by the board, or by the California Board of Podiatric Medicine, whichever is applicable, who, except for good cause, knowingly fail to protect patients by failing to follow infection control guidelines of the applicable board, thereby risking transmission of blood-borne infectious diseases from the physician and surgeon or other health care provider licensed or regulated by the applicable board to patients, from patients, and from patient to physician and surgeon or other health care provider regulated by the applicable board. In so doing, the boards shall consider referencing the standards, regulations, and guidelines of the State Department of Health Services developed pursuant to Section 1250.11 of the Health and Safety Code and the standards, guidelines, and regulations pursuant to the California Occupational Safety and Health Act of 1973 (Part 1 (commencing with Section 6300), Division 5, Labor Code) for preventing the transmission of HIV, hepatitis B, and other blood-borne pathogens in health care settings. As necessary, the board and the California Board of Podiatric Medicine shall consult with the Board of Dental Examiners, the Board of Registered Nursing, and the Board of Vocational Nursing and Psychiatric Technicians, to encourage appropriate consistency in the implementation of this section.
(b)Subdivision (a) shall not apply to an organ transplant performed within the standard of care and in compliance with subdivision (d) of Section 1644.5 of the Health and Safety Code.
(c)The board shall seek to ensure that licentiates and others regulated by the board are informed of the responsibility of licentiates to follow infection control guidelines and of the most recent scientifically recognized safeguards for minimizing the transmission of blood-borne infectious diseases.
SEC. 2.Section 1621.5 of the Health and Safety Code is amended to read:1621.5.(a) It is a felony punishable by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code for two, four, or six years, for any person to donate blood or tissue, semen to any medical center or semen bank that receives semen for purposes of artificial insemination, or breast milk to any medical center or breast milk bank that receives breast milk for purposes of distribution, whether he or she is a paid or a volunteer donor, who knows that he or she has acquired immunodeficiency syndrome (AIDS), as diagnosed by a physician and surgeon, or who knows that he or she has tested reactive to HIV. This section shall not apply to any person who is mentally incompetent or who self-defers his or her blood at a blood bank or plasma center pursuant to subdivision (b) of Section 1603.3 or who donates his or her blood for purposes of an autologous donation.
(b) In a criminal investigation for a violation of this section, no person shall disclose the results of a blood test to detect the etiologic agent of AIDS or antibodies to that agent to any officer, employee, or agent of a state or local agency or department unless the test results are disclosed as otherwise required by law pursuant to any one of the following:
(1) A search warrant issued pursuant to Section 1524 of the Penal Code.
(2) A judicial subpoena or subpoena duces tecum issued and served in compliance with Chapter 2 (commencing with Section 1985) of Title 3 of Part 4 of the Code of Civil Procedure.
(3) An order of a court.
(c) For purposes of this section, blood means human whole blood and human whole blood derivatives, as defined for purposes of this chapter and includes blood components, as defined in subdivision (k) of Section 1603.1.
(d)For purposes of this section, tissue shall have the same meaning as defined in paragraph (1) of subdivision (c) of Section 1635.
SEC. 3.Section 1635 of the Health and Safety Code is amended to read:1635.(a)Donor means an individual, living or deceased, from whom tissue is removed.
(b)Person means an individual, corporation, business trust, estate trust, partnership, association, state or local government, or subdivision or agency thereof, or any other legal entity.
(c)(1)Tissue means a human cell, group of cells, including the cornea, sclera, or vitreous humor and other segments of, or the whole eye, bones, skin, arteries, sperm, blood, other fluids, and any other portion of a human body, but shall not include an organ when recovered for transplantation or research purposes.
(2)For purposes of paragraph (1), organ means a human kidney, liver, heart, lung, pancreas, intestine (including the esophagus, stomach, small or large intestine, or any portion of the gastrointestinal tract), or vascularized composite allograft, and associated blood vessels recovered from an organ donor during the recovery of the organ.
(d)Tissue bank means a place, establishment, or institution that collects, processes, stores, or distributes tissue for transplantation into human beings.
(e)Transplantation means the act or process of transferring tissue, including by ingestion, from a donor to the body of the donor or another human being.
(f)Department means the State Department of Public Health.
SEC. 4.Section 1635.1 of the Health and Safety Code is amended to read:1635.1.(a)Except as provided in subdivision (b), every tissue bank operating in California on or after July 1, 1992, shall have a current and valid tissue bank license issued or renewed by the department pursuant to Section 1639.2 or 1639.3.
(b)This chapter does not apply to any of the following:
(1)The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed pursuant to Chapter 4 (commencing with Section 1600) or any person exempt from licensure under that chapter.
(2)The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable.
(3)The collection of tissue by an individual physician and surgeon from his or her patient or the implantation of tissue by an individual physician and surgeon into his or her patient. This exemption shall not be interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter.
(4)The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus.
(5)The collection, processing, storage, or distribution by an organ procurement organization (OPO), as defined in Section 485.302 of Title 42 of the Code of Federal Regulations, if the OPO, at the time of collection, processing, storage, and distribution of the tissue, has been designated by the Secretary of Health and Human Services as an OPO, pursuant to Section 485.305 of Title 42 of the Code of Federal Regulations, and meets the requirements of Sections 485.304 and 485.306 of Title 42 of the Code of Federal Regulations, as applicable.
(6)The storage of prepackaged, freeze-dried bone by a general acute care hospital.
(7)The storage of freeze-dried bone and dermis by any licensed dentist practicing in a lawful practice setting, if the freeze-dried bone and dermis has been obtained from a licensed tissue bank, is stored in strict accordance with a kits package insert and any other manufacturer instructions and guidelines, and is used for the express purpose of implantation into a patient.
(8)The storage of a human cell, tissue, or cellular- or tissue-based product, as defined by the federal Food and Drug Administration, that is either a medical device approved pursuant to Section 510 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Secs. 360 and 360e) or that is a biologic product approved under Section 351 of the federal Public Health Service Act (42 U.S.C. Sec. 262) by a licensed physician or podiatrist acting within the scope and authority of his or her license and practicing in a lawful practice setting. The medical device or biologic product must have been obtained from a California licensed tissue bank, been stored in strict accordance with the devices or products package insert and any other manufacturer instructions, and used solely for the express purpose of direct implantation into or application on the practitioners own patient. In order to be eligible for the exemption in this paragraph, the entity or organization where the physician or podiatrist who is eligible for the exemption is practicing shall notify the department, in writing, that the practitioner is licensed and meets the requirements of this paragraph. The notification shall include all of the following:
(A)A list of all practitioners to whom the notice applies.
(B)Acknowledgment that each listed practitioner uses the medical device or biologic product in the scope and authority of his or her license and practice for the purposes of direct patient care as described in this paragraph.
(C)A statement that each listed practitioner agrees to strictly abide by the directions for storage in the devices or products package insert and any other manufacturer instructions and guidelines.
(D)Acknowledgment by each practitioner that the medical device or biologic product shall not be resold or distributed.
(9)The collection, processing, storage, or distribution of any organ, as defined in paragraph (2) of subdivision (c) of Section 1635, within a single general acute care hospital, as defined in subdivision (a) of Section 1250, operating a Medicare-approved transplant program.
SEC. 5.Section 1644.5 of the Health and Safety Code is amended to read:1644.5.(a)Except as provided in subdivision (c) or (d), no tissues shall be transferred into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive by laboratory tests for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), and syphilis. For tissues that are rich in viable leukocytes, the tissue shall be tested for evidence of infection with human T lymphotropic virus (HTLV) and found nonreactive. The department may adopt regulations requiring additional screening tests of donors of tissues when, in the opinion of the department, the action is necessary for the protection of the public, donors, or recipients.
(b)Notwithstanding subdivision (a), infectious disease screening of blood and blood products shall be carried out solely in accordance with Article 2 (commencing with Section 1602.5) of Chapter 4.
(c)All donors of sperm shall be screened and found nonreactive as required under subdivision (a), except in the following instances:
(1)A recipient of sperm, from a sperm donor known to the recipient, may waive a second or other repeat testing of that donor if the recipient is informed of the requirements for testing donors under this section and signs a written waiver.
(2)A recipient of sperm may consent to therapeutic insemination of sperm or use of sperm in other assisted reproductive technologies even if the sperm donor is found reactive for hepatitis B, hepatitis C, syphilis, HIV, or HTLV if the sperm donor is the spouse of, partner of, or designated donor for that recipient. The physician providing insemination or assisted reproductive technology services shall advise the donor and recipient of the potential medical risks associated with receiving sperm from a reactive donor. The donor and the recipient shall sign a document affirming that each comprehends the potential medical risks of using sperm from a reactive donor for the proposed procedure and that each consents to it. Copies of the document shall be placed in the medical records of the donor and the recipient.
(3)(A)Sperm whose donor has tested reactive for syphilis may be used for the purposes of insemination or assisted reproductive technology only after the donor has been treated for syphilis. Sperm whose donor has tested reactive for hepatitis B may be used for the purposes of insemination or assisted reproductive technology only after the recipient has been vaccinated against hepatitis B.
(B)(i)Sperm whose donor has tested reactive for HIV or HTLV may be used for the purposes of insemination or assisted reproductive technology for a recipient testing negative for HIV or HTLV only after the donors sperm has been effectively processed to minimize the infectiousness of the sperm for that specific donation and where informed and mutual consent has occurred.
(ii)The department shall adopt regulations regulating facilities that perform sperm processing, pursuant to this subparagraph, that prescribe standards for the handling and storage of sperm samples of carriers of HIV, HTLV, or any other virus as deemed appropriate by the department. The department may propose to adopt, as initial regulations, the recommendations made within the Guidelines for Reducing Risk of Viral Transmission During Fertility Treatment as published by the American Society for Reproductive Medicine. Notice of the departments proposed adoption of the regulations shall be posted on the departments Internet Web site for at least 45 days. Public comment shall be accepted by the department for at least 30 days after the conclusion of the 45-day posting period. If a member of the public requests a public hearing during the 30-day comment period, the hearing shall be held prior to the adoption of the regulations. If no member of the public requests a public hearing, the regulations shall be deemed adopted at the conclusion of the 30-day comment period. Comments received shall be considered prior to the adoption of the final initial regulations. The department may modify any guidance published by the American Society for Reproductive Medicine. Adoption of initial regulations by the department pursuant to this subdivision shall not be subject to the rulemaking requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code and written responses to public comments shall not be required. Updates to the regulations shall be adopted pursuant to the same process. Until the department adopts these regulations, facilities that perform sperm processing pursuant to this section shall follow facility and sperm processing guidelines for the reduction of viral transmission developed by the American Society for Reproductive Medicine. Nothing in this section shall prevent the department from monitoring and inspecting facilities that process sperm to ensure adherence to the regulations, or, until regulations are adopted, to the guidelines set forth by the American Society for Reproductive Medicine.
(iii)Prior to insemination or other assisted reproductive technology services, the physician providing the services shall inform the recipient of sperm from a spouse, partner, or designated donor who has tested reactive for HIV or HTLV of all of the following:
(I)That sperm processing may not eliminate all of the risks of HIV or HTLV transmission.
(II)That the sperm may be tested to determine whether or not it is reactive for HIV or HTLV.
(III)That the recipient must provide documentation to the physician providing insemination or assisted reproductive technology services prior to treatment that she has established an ongoing relationship with another physician to provide for her medical care during and after completion of fertility services.
(IV)The recommendations made within the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine regarding followup testing for HIV and HTLV after use of sperm from an HIV or HTLV reactive donor and have the recommendations regarding followup testing be documented in the recipients medical record.
(iv)The physician providing insemination or assisted reproductive technology services shall also verify, and document in the recipients medical record, that the donor of sperm who tests reactive for HIV or HTLV is under the care of a physician managing the HIV or HTLV.
(v)The physician providing insemination or assisted reproductive technology services shall recommend to the physician who will be providing ongoing care to the recipient recommended followup testing for HIV and HTLV according to the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine, which shall be documented in the recipients medical record.
(vi)If the recipient becomes HIV or HTLV positive, the physician assuming ongoing care of the recipient shall treat or provide information regarding referral to a physician who can provide ongoing treatment of the HIV or HTLV.
(4)A recipient of sperm donated by a sexually intimate partner of the recipient for reproductive use may waive a second or repeat testing of that donor if the recipient is informed of the donor testing requirements of this section and signs a written waiver. For purposes of this paragraph, sexually intimate partner of the recipient includes a known or designated donor to whose sperm the recipient has previously been exposed in a nonmedical setting in an attempt to conceive.
(d)Subdivision (a) shall not apply to the transplantation of tissue from a donor who has not been tested or, with the exception of HTLV, has been found reactive for the infectious diseases listed in subdivision (a) or for which the department has, by regulation, required additional screening tests, if all of the following conditions are satisfied:
(1)The physician and surgeon performing the transplantation has determined any one or more of the following:
(A)Without the transplantation the intended recipient will most likely die during the period of time necessary to obtain other tissue or to conduct the required tests.
(B)The intended recipient already is diagnosed with the infectious disease for which the donor has tested positive.
(C)The symptoms from the infectious disease for which the donor has tested positive will most likely not appear during the intended recipients likely lifespan after transplantation with the tissue or may be treated prophylactically if they do appear.
(2)The physician and surgeon performing the transplantation has ensured that an organ from an individual who has been found reactive for HIV may be transplanted only into an individual who satisfies both of the following:
(A)The individual has been found reactive for HIV before receiving the organ.
(B)The individual is either participating in clinical research approved by an institutional review board under the criteria, standards, and regulations described in subsections (a) and (b) of Section 274f-5 of Title 42 of the United States Code, or, if the United States Secretary of Health and Human Services determines under subsection (c) of Section 274f-5 of Title 42 of the United States Code that participation in this clinical research is no longer warranted as a requirement for transplants, the individual is receiving the transplant under the standards and regulations under subsection (c) of Section 274f-5 of Title 42 of the United States Code.
(3)Consent for the use of the tissue has been obtained from the recipient, if possible, or if not possible, from a member of the recipients family, or the recipients legal guardian. For purposes of this section, family shall mean spouse, adult son or daughter, either parent, adult brother or sister, or grandparent.
(e)The penalties prescribed in Sections 1621.5 and 120290 do not apply to a sperm donor covered under subdivision (c) or an organ donor who donates an organ for transplantation or research purposes.
(f)Human breast milk from donors who test reactive for agents of viral hepatitis (HBV and HCV), HTLV, HIV, or syphilis shall not be used for deposit into a milk bank for human ingestion in California.
SEC. 6.Section 120290 of the Health and Safety Code is amended to read:120290.(a)Except as provided in Section 120291 or in the case of the removal of an afflicted person in a manner the least dangerous to the public health, any person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, and any person who willfully exposes another person afflicted with the disease to someone else, is guilty of a misdemeanor.
(b)This section shall not apply to a person who donates an organ for transplantation or research purposes.
SEC. 7.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to provide for organ donations and transplants to occur at the earliest opportunity, it is necessary that this act take effect immediately.
(a)The board and the California Board of Podiatric Medicine shall investigate and may take disciplinary action, including, but not limited to, revocation or suspension of licenses, against physicians and surgeons and all others licensed or regulated by the board, or by the California Board of Podiatric Medicine, whichever is applicable, who, except for good cause, knowingly fail to protect patients by failing to follow infection control guidelines of the applicable board, thereby risking transmission of blood-borne infectious diseases from the physician and surgeon or other health care provider licensed or regulated by the applicable board to patients, from patients, and from patient to physician and surgeon or other health care provider regulated by the applicable board. In so doing, the boards shall consider referencing the standards, regulations, and guidelines of the State Department of Health Services developed pursuant to Section 1250.11 of the Health and Safety Code and the standards, guidelines, and regulations pursuant to the California Occupational Safety and Health Act of 1973 (Part 1 (commencing with Section 6300), Division 5, Labor Code) for preventing the transmission of HIV, hepatitis B, and other blood-borne pathogens in health care settings. As necessary, the board and the California Board of Podiatric Medicine shall consult with the Board of Dental Examiners, the Board of Registered Nursing, and the Board of Vocational Nursing and Psychiatric Technicians, to encourage appropriate consistency in the implementation of this section.
(b)Subdivision (a) shall not apply to an organ transplant performed within the standard of care and in compliance with subdivision (d) of Section 1644.5 of the Health and Safety Code.
(c)The board shall seek to ensure that licentiates and others regulated by the board are informed of the responsibility of licentiates to follow infection control guidelines and of the most recent scientifically recognized safeguards for minimizing the transmission of blood-borne infectious diseases.
SEC. 2.Section 1621.5 of the Health and Safety Code is amended to read:1621.5.(a) It is a felony punishable by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code for two, four, or six years, for any person to donate blood or tissue, semen to any medical center or semen bank that receives semen for purposes of artificial insemination, or breast milk to any medical center or breast milk bank that receives breast milk for purposes of distribution, whether he or she is a paid or a volunteer donor, who knows that he or she has acquired immunodeficiency syndrome (AIDS), as diagnosed by a physician and surgeon, or who knows that he or she has tested reactive to HIV. This section shall not apply to any person who is mentally incompetent or who self-defers his or her blood at a blood bank or plasma center pursuant to subdivision (b) of Section 1603.3 or who donates his or her blood for purposes of an autologous donation.
(b) In a criminal investigation for a violation of this section, no person shall disclose the results of a blood test to detect the etiologic agent of AIDS or antibodies to that agent to any officer, employee, or agent of a state or local agency or department unless the test results are disclosed as otherwise required by law pursuant to any one of the following:
(1) A search warrant issued pursuant to Section 1524 of the Penal Code.
(2) A judicial subpoena or subpoena duces tecum issued and served in compliance with Chapter 2 (commencing with Section 1985) of Title 3 of Part 4 of the Code of Civil Procedure.
(3) An order of a court.
(c) For purposes of this section, blood means human whole blood and human whole blood derivatives, as defined for purposes of this chapter and includes blood components, as defined in subdivision (k) of Section 1603.1.
(d)For purposes of this section, tissue shall have the same meaning as defined in paragraph (1) of subdivision (c) of Section 1635.
SEC. 3.Section 1635 of the Health and Safety Code is amended to read:1635.(a)Donor means an individual, living or deceased, from whom tissue is removed.
(b)Person means an individual, corporation, business trust, estate trust, partnership, association, state or local government, or subdivision or agency thereof, or any other legal entity.
(c)(1)Tissue means a human cell, group of cells, including the cornea, sclera, or vitreous humor and other segments of, or the whole eye, bones, skin, arteries, sperm, blood, other fluids, and any other portion of a human body, but shall not include an organ when recovered for transplantation or research purposes.
(2)For purposes of paragraph (1), organ means a human kidney, liver, heart, lung, pancreas, intestine (including the esophagus, stomach, small or large intestine, or any portion of the gastrointestinal tract), or vascularized composite allograft, and associated blood vessels recovered from an organ donor during the recovery of the organ.
(d)Tissue bank means a place, establishment, or institution that collects, processes, stores, or distributes tissue for transplantation into human beings.
(e)Transplantation means the act or process of transferring tissue, including by ingestion, from a donor to the body of the donor or another human being.
(f)Department means the State Department of Public Health.
SEC. 4.Section 1635.1 of the Health and Safety Code is amended to read:1635.1.(a)Except as provided in subdivision (b), every tissue bank operating in California on or after July 1, 1992, shall have a current and valid tissue bank license issued or renewed by the department pursuant to Section 1639.2 or 1639.3.
(b)This chapter does not apply to any of the following:
(1)The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed pursuant to Chapter 4 (commencing with Section 1600) or any person exempt from licensure under that chapter.
(2)The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable.
(3)The collection of tissue by an individual physician and surgeon from his or her patient or the implantation of tissue by an individual physician and surgeon into his or her patient. This exemption shall not be interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter.
(4)The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus.
(5)The collection, processing, storage, or distribution by an organ procurement organization (OPO), as defined in Section 485.302 of Title 42 of the Code of Federal Regulations, if the OPO, at the time of collection, processing, storage, and distribution of the tissue, has been designated by the Secretary of Health and Human Services as an OPO, pursuant to Section 485.305 of Title 42 of the Code of Federal Regulations, and meets the requirements of Sections 485.304 and 485.306 of Title 42 of the Code of Federal Regulations, as applicable.
(6)The storage of prepackaged, freeze-dried bone by a general acute care hospital.
(7)The storage of freeze-dried bone and dermis by any licensed dentist practicing in a lawful practice setting, if the freeze-dried bone and dermis has been obtained from a licensed tissue bank, is stored in strict accordance with a kits package insert and any other manufacturer instructions and guidelines, and is used for the express purpose of implantation into a patient.
(8)The storage of a human cell, tissue, or cellular- or tissue-based product, as defined by the federal Food and Drug Administration, that is either a medical device approved pursuant to Section 510 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Secs. 360 and 360e) or that is a biologic product approved under Section 351 of the federal Public Health Service Act (42 U.S.C. Sec. 262) by a licensed physician or podiatrist acting within the scope and authority of his or her license and practicing in a lawful practice setting. The medical device or biologic product must have been obtained from a California licensed tissue bank, been stored in strict accordance with the devices or products package insert and any other manufacturer instructions, and used solely for the express purpose of direct implantation into or application on the practitioners own patient. In order to be eligible for the exemption in this paragraph, the entity or organization where the physician or podiatrist who is eligible for the exemption is practicing shall notify the department, in writing, that the practitioner is licensed and meets the requirements of this paragraph. The notification shall include all of the following:
(A)A list of all practitioners to whom the notice applies.
(B)Acknowledgment that each listed practitioner uses the medical device or biologic product in the scope and authority of his or her license and practice for the purposes of direct patient care as described in this paragraph.
(C)A statement that each listed practitioner agrees to strictly abide by the directions for storage in the devices or products package insert and any other manufacturer instructions and guidelines.
(D)Acknowledgment by each practitioner that the medical device or biologic product shall not be resold or distributed.
(9)The collection, processing, storage, or distribution of any organ, as defined in paragraph (2) of subdivision (c) of Section 1635, within a single general acute care hospital, as defined in subdivision (a) of Section 1250, operating a Medicare-approved transplant program.
SEC. 5.Section 1644.5 of the Health and Safety Code is amended to read:1644.5.(a)Except as provided in subdivision (c) or (d), no tissues shall be transferred into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive by laboratory tests for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), and syphilis. For tissues that are rich in viable leukocytes, the tissue shall be tested for evidence of infection with human T lymphotropic virus (HTLV) and found nonreactive. The department may adopt regulations requiring additional screening tests of donors of tissues when, in the opinion of the department, the action is necessary for the protection of the public, donors, or recipients.
(b)Notwithstanding subdivision (a), infectious disease screening of blood and blood products shall be carried out solely in accordance with Article 2 (commencing with Section 1602.5) of Chapter 4.
(c)All donors of sperm shall be screened and found nonreactive as required under subdivision (a), except in the following instances:
(1)A recipient of sperm, from a sperm donor known to the recipient, may waive a second or other repeat testing of that donor if the recipient is informed of the requirements for testing donors under this section and signs a written waiver.
(2)A recipient of sperm may consent to therapeutic insemination of sperm or use of sperm in other assisted reproductive technologies even if the sperm donor is found reactive for hepatitis B, hepatitis C, syphilis, HIV, or HTLV if the sperm donor is the spouse of, partner of, or designated donor for that recipient. The physician providing insemination or assisted reproductive technology services shall advise the donor and recipient of the potential medical risks associated with receiving sperm from a reactive donor. The donor and the recipient shall sign a document affirming that each comprehends the potential medical risks of using sperm from a reactive donor for the proposed procedure and that each consents to it. Copies of the document shall be placed in the medical records of the donor and the recipient.
(3)(A)Sperm whose donor has tested reactive for syphilis may be used for the purposes of insemination or assisted reproductive technology only after the donor has been treated for syphilis. Sperm whose donor has tested reactive for hepatitis B may be used for the purposes of insemination or assisted reproductive technology only after the recipient has been vaccinated against hepatitis B.
(B)(i)Sperm whose donor has tested reactive for HIV or HTLV may be used for the purposes of insemination or assisted reproductive technology for a recipient testing negative for HIV or HTLV only after the donors sperm has been effectively processed to minimize the infectiousness of the sperm for that specific donation and where informed and mutual consent has occurred.
(ii)The department shall adopt regulations regulating facilities that perform sperm processing, pursuant to this subparagraph, that prescribe standards for the handling and storage of sperm samples of carriers of HIV, HTLV, or any other virus as deemed appropriate by the department. The department may propose to adopt, as initial regulations, the recommendations made within the Guidelines for Reducing Risk of Viral Transmission During Fertility Treatment as published by the American Society for Reproductive Medicine. Notice of the departments proposed adoption of the regulations shall be posted on the departments Internet Web site for at least 45 days. Public comment shall be accepted by the department for at least 30 days after the conclusion of the 45-day posting period. If a member of the public requests a public hearing during the 30-day comment period, the hearing shall be held prior to the adoption of the regulations. If no member of the public requests a public hearing, the regulations shall be deemed adopted at the conclusion of the 30-day comment period. Comments received shall be considered prior to the adoption of the final initial regulations. The department may modify any guidance published by the American Society for Reproductive Medicine. Adoption of initial regulations by the department pursuant to this subdivision shall not be subject to the rulemaking requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code and written responses to public comments shall not be required. Updates to the regulations shall be adopted pursuant to the same process. Until the department adopts these regulations, facilities that perform sperm processing pursuant to this section shall follow facility and sperm processing guidelines for the reduction of viral transmission developed by the American Society for Reproductive Medicine. Nothing in this section shall prevent the department from monitoring and inspecting facilities that process sperm to ensure adherence to the regulations, or, until regulations are adopted, to the guidelines set forth by the American Society for Reproductive Medicine.
(iii)Prior to insemination or other assisted reproductive technology services, the physician providing the services shall inform the recipient of sperm from a spouse, partner, or designated donor who has tested reactive for HIV or HTLV of all of the following:
(I)That sperm processing may not eliminate all of the risks of HIV or HTLV transmission.
(II)That the sperm may be tested to determine whether or not it is reactive for HIV or HTLV.
(III)That the recipient must provide documentation to the physician providing insemination or assisted reproductive technology services prior to treatment that she has established an ongoing relationship with another physician to provide for her medical care during and after completion of fertility services.
(IV)The recommendations made within the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine regarding followup testing for HIV and HTLV after use of sperm from an HIV or HTLV reactive donor and have the recommendations regarding followup testing be documented in the recipients medical record.
(iv)The physician providing insemination or assisted reproductive technology services shall also verify, and document in the recipients medical record, that the donor of sperm who tests reactive for HIV or HTLV is under the care of a physician managing the HIV or HTLV.
(v)The physician providing insemination or assisted reproductive technology services shall recommend to the physician who will be providing ongoing care to the recipient recommended followup testing for HIV and HTLV according to the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine, which shall be documented in the recipients medical record.
(vi)If the recipient becomes HIV or HTLV positive, the physician assuming ongoing care of the recipient shall treat or provide information regarding referral to a physician who can provide ongoing treatment of the HIV or HTLV.
(4)A recipient of sperm donated by a sexually intimate partner of the recipient for reproductive use may waive a second or repeat testing of that donor if the recipient is informed of the donor testing requirements of this section and signs a written waiver. For purposes of this paragraph, sexually intimate partner of the recipient includes a known or designated donor to whose sperm the recipient has previously been exposed in a nonmedical setting in an attempt to conceive.
(d)Subdivision (a) shall not apply to the transplantation of tissue from a donor who has not been tested or, with the exception of HTLV, has been found reactive for the infectious diseases listed in subdivision (a) or for which the department has, by regulation, required additional screening tests, if all of the following conditions are satisfied:
(1)The physician and surgeon performing the transplantation has determined any one or more of the following:
(A)Without the transplantation the intended recipient will most likely die during the period of time necessary to obtain other tissue or to conduct the required tests.
(B)The intended recipient already is diagnosed with the infectious disease for which the donor has tested positive.
(C)The symptoms from the infectious disease for which the donor has tested positive will most likely not appear during the intended recipients likely lifespan after transplantation with the tissue or may be treated prophylactically if they do appear.
(2)The physician and surgeon performing the transplantation has ensured that an organ from an individual who has been found reactive for HIV may be transplanted only into an individual who satisfies both of the following:
(A)The individual has been found reactive for HIV before receiving the organ.
(B)The individual is either participating in clinical research approved by an institutional review board under the criteria, standards, and regulations described in subsections (a) and (b) of Section 274f-5 of Title 42 of the United States Code, or, if the United States Secretary of Health and Human Services determines under subsection (c) of Section 274f-5 of Title 42 of the United States Code that participation in this clinical research is no longer warranted as a requirement for transplants, the individual is receiving the transplant under the standards and regulations under subsection (c) of Section 274f-5 of Title 42 of the United States Code.
(3)Consent for the use of the tissue has been obtained from the recipient, if possible, or if not possible, from a member of the recipients family, or the recipients legal guardian. For purposes of this section, family shall mean spouse, adult son or daughter, either parent, adult brother or sister, or grandparent.
(e)The penalties prescribed in Sections 1621.5 and 120290 do not apply to a sperm donor covered under subdivision (c) or an organ donor who donates an organ for transplantation or research purposes.
(f)Human breast milk from donors who test reactive for agents of viral hepatitis (HBV and HCV), HTLV, HIV, or syphilis shall not be used for deposit into a milk bank for human ingestion in California.
SEC. 6.Section 120290 of the Health and Safety Code is amended to read:120290.(a)Except as provided in Section 120291 or in the case of the removal of an afflicted person in a manner the least dangerous to the public health, any person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, and any person who willfully exposes another person afflicted with the disease to someone else, is guilty of a misdemeanor.
(b)This section shall not apply to a person who donates an organ for transplantation or research purposes.
SEC. 7.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to provide for organ donations and transplants to occur at the earliest opportunity, it is necessary that this act take effect immediately.
(a)The board and the California Board of Podiatric Medicine shall investigate and may take disciplinary action, including, but not limited to, revocation or suspension of licenses, against physicians and surgeons and all others licensed or regulated by the board, or by the California Board of Podiatric Medicine, whichever is applicable, who, except for good cause, knowingly fail to protect patients by failing to follow infection control guidelines of the applicable board, thereby risking transmission of blood-borne infectious diseases from the physician and surgeon or other health care provider licensed or regulated by the applicable board to patients, from patients, and from patient to physician and surgeon or other health care provider regulated by the applicable board. In so doing, the boards shall consider referencing the standards, regulations, and guidelines of the State Department of Health Services developed pursuant to Section 1250.11 of the Health and Safety Code and the standards, guidelines, and regulations pursuant to the California Occupational Safety and Health Act of 1973 (Part 1 (commencing with Section 6300), Division 5, Labor Code) for preventing the transmission of HIV, hepatitis B, and other blood-borne pathogens in health care settings. As necessary, the board and the California Board of Podiatric Medicine shall consult with the Board of Dental Examiners, the Board of Registered Nursing, and the Board of Vocational Nursing and Psychiatric Technicians, to encourage appropriate consistency in the implementation of this section.
(b)Subdivision (a) shall not apply to an organ transplant performed in compliance with subdivision (d) of Section 1644.5 of the Health and Safety Code.
(b)
(c)The board shall seek to ensure that licentiates and others regulated by the board are informed of the responsibility of licentiates to follow infection control guidelines and of the most recent scientifically recognized safeguards for minimizing the transmission of blood-borne infectious diseases.
SEC. 2.Section 1621.5 of the Health and Safety Code is amended to read:1621.5.(a) It is a felony punishable by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code for two, four, or six years, for any person to donate blood, body organs or other blood or tissue, semen to any medical center or semen bank that receives semen for purposes of artificial insemination, or breast milk to any medical center or breast milk bank that receives breast milk for purposes of distribution, whether he or she is a paid or a volunteer donor, who knows that he or she has acquired immunodeficiency syndrome (AIDS), as diagnosed by a physician and surgeon, or who knows that he or she has tested reactive to HIV. This section shall not apply to any person who is mentally incompetent or who self-defers his or her blood at a blood bank or plasma center pursuant to subdivision (b) of Section 1603.3 or who donates his or her blood for purposes of an autologous donation.
(b) In a criminal investigation for a violation of this section, no person shall disclose the results of a blood test to detect the etiologic agent of AIDS or antibodies to that agent to any officer, employee, or agent of a state or local agency or department unless the test results are disclosed as otherwise required by law pursuant to any one of the following:
(1) A search warrant issued pursuant to Section 1524 of the Penal Code.
(2) A judicial subpoena or subpoena duces tecum issued and served in compliance with Chapter 2 (commencing with Section 1985) of Title 3 of Part 4 of the Code of Civil Procedure.
(3) An order of a court.
(c) For purposes of this section, blood means human whole blood and human whole blood derivatives, as defined for purposes of this chapter and includes blood components, as defined in subdivision (k) of Section 1603.1.
(d)For purposes of this section, tissue shall have the same meaning as defined in paragraph (1) of subdivision (c) of Section 1635.
SEC. 3.Section 1635 of the Health and Safety Code is amended to read:1635.(a)Donor means an individual, living or deceased, from whom tissue is removed.
(b)Person means an individual, corporation, business trust, estate trust, partnership, association, state or local government, or subdivision or agency thereof, or any other legal entity.
(c)(1)Tissue means a human cell, group of cells, including the cornea, sclera, or vitreous humor and other segments of, or the whole eye, bones, skin, arteries, sperm, blood, other fluids, and any other portion of a human body. body, but shall not include an organ when recovered for transplantation or research purposes.
(2)For purposes of paragraph (1), organ means a human kidney, liver, heart, lung, pancreas, intestine (including the esophagus, stomach, small or large intestine, or any portion of the gastrointestinal tract), or vascularized composite allograft, and associated blood vessels recovered from an organ donor during the recovery of the organ.
(d)Tissue bank means a place, establishment, or institution that collects, processes, stores, or distributes tissue for transplantation into human beings.
(e)Transplantation means the act or process of transferring tissue, including by ingestion, from a donor to the body of the donor or another human being.
(f)Department means the State Department of Public Health.
SEC. 4.Section 1635.1 of the Health and Safety Code is amended to read:1635.1.(a)Except as provided in subdivision (b), every tissue bank operating in California on or after July 1, 1992, shall have a current and valid tissue bank license issued or renewed by the department pursuant to Section 1639.2 or 1639.3.
(b)This chapter does not apply to any of the following:
(1)The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed pursuant to Chapter 4 (commencing with Section 1600) or any person exempt from licensure under that chapter.
(2)The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable.
(3)The collection of tissue by an individual physician and surgeon from his or her patient or the implantation of tissue by an individual physician and surgeon into his or her patient. This exemption shall not be interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter.
(4)The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus.
(5)The collection, processing, storage, or distribution by an organ procurement organization (OPO), as defined in Section 485.302 of Title 42 of the Code of Federal Regulations, if the OPO, at the time of collection, processing, storage, and distribution of the organ, tissue, has been designated by the Secretary of Health and Human Services as an OPO, pursuant to Section 485.305 of Title 42 of the Code of Federal Regulations, and meets the requirements of Sections 485.304 and 485.306 of Title 42 of the Code of Federal Regulations, as applicable.
(6)The storage of prepackaged, freeze-dried bone by a general acute care hospital.
(7)The storage of freeze-dried bone and dermis by any licensed dentist practicing in a lawful practice setting, if the freeze-dried bone and dermis has been obtained from a licensed tissue bank, is stored in strict accordance with a kits package insert and any other manufacturer instructions and guidelines, and is used for the express purpose of implantation into a patient.
(8)The storage of a human cell, tissue, or cellular- or tissue-based product, as defined by the federal Food and Drug Administration, that is either a medical device approved pursuant to Section 510 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Secs. 360 and 360e) or that is a biologic product approved under Section 351 of the federal Public Health Service Act (42 U.S.C. Sec. 262) by a licensed physician or podiatrist acting within the scope and authority of his or her license and practicing in a lawful practice setting. The medical device or biologic product must have been obtained from a California licensed tissue bank, been stored in strict accordance with the devices or products package insert and any other manufacturer instructions, and used solely for the express purpose of direct implantation into or application on the practitioners own patient. In order to be eligible for the exemption in this paragraph, the entity or organization where the physician or podiatrist who is eligible for the exemption is practicing shall notify the department, in writing, that the practitioner is licensed and meets the requirements of this paragraph. The notification shall include all of the following:
(A)A list of all practitioners to whom the notice applies.
(B)Acknowledgment that each listed practitioner uses the medical device or biologic product in the scope and authority of his or her license and practice for the purposes of direct patient care as described in this paragraph.
(C)A statement that each listed practitioner agrees to strictly abide by the directions for storage in the devices or products package insert and any other manufacturer instructions and guidelines.
(D)Acknowledgment by each practitioner that the medical device or biologic product shall not be resold or distributed.
(9)The collection, processing, storage, or distribution of any organ, as defined in paragraph (2) of subdivision (c) of Section 1635, within a single general acute care hospital, as defined in subdivision (a) of Section 1250, operating a Medicare-approved transplant program.
SECTION 1.SEC. 5.Section 1644.5 of the Health and Safety Code is amended to read:1644.5.(a)Except as provided in subdivision (c) or (d), no tissues shall be transferred into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive by laboratory tests for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), and syphilis. For tissues that are rich in viable leukocytes, the tissue shall be tested for evidence of infection with human T lymphotropic virus (HTLV) and found nonreactive. The department may adopt regulations requiring additional screening tests of donors of tissues when, in the opinion of the department, the action is necessary for the protection of the public, donors, or recipients.
(b)Notwithstanding subdivision (a), infectious disease screening of blood and blood products shall be carried out solely in accordance with Article 2 (commencing with Section 1602.5) of Chapter 4.
(c)All donors of sperm shall be screened and found nonreactive as required under subdivision (a), except in the following instances:
(1)A recipient of sperm, from a sperm donor known to the recipient, may waive a second or other repeat testing of that donor if the recipient is informed of the requirements for testing donors under this section and signs a written waiver.
(2)A recipient of sperm may consent to therapeutic insemination of sperm or use of sperm in other assisted reproductive technologies even if the sperm donor is found reactive for hepatitis B, hepatitis C, syphilis, HIV, or HTLV if the sperm donor is the spouse of, partner of, or designated donor for that recipient. The physician providing insemination or assisted reproductive technology services shall advise the donor and recipient of the potential medical risks associated with receiving sperm from a reactive donor. The donor and the recipient shall sign a document affirming that each comprehends the potential medical risks of using sperm from a reactive donor for the proposed procedure and that each consents to it. Copies of the document shall be placed in the medical records of the donor and the recipient.
(3)(A)Sperm whose donor has tested reactive for syphilis may be used for the purposes of insemination or assisted reproductive technology only after the donor has been treated for syphilis. Sperm whose donor has tested reactive for hepatitis B may be used for the purposes of insemination or assisted reproductive technology only after the recipient has been vaccinated against hepatitis B.
(B)(i)Sperm whose donor has tested reactive for HIV or HTLV may be used for the purposes of insemination or assisted reproductive technology for a recipient testing negative for HIV or HTLV only after the donors sperm has been effectively processed to minimize the infectiousness of the sperm for that specific donation and where informed and mutual consent has occurred.
(ii)The department shall adopt regulations regulating facilities that perform sperm processing, pursuant to this subparagraph, that prescribe standards for the handling and storage of sperm samples of carriers of HIV, HTLV, or any other virus as deemed appropriate by the department. The department may propose to adopt, as initial regulations, the recommendations made within the Guidelines for Reducing Risk of Viral Transmission During Fertility Treatment as published by the American Society for Reproductive Medicine. Notice of the departments proposed adoption of the regulations shall be posted on the departments Internet Web site for at least 45 days. Public comment shall be accepted by the department for at least 30 days after the conclusion of the 45-day posting period. If a member of the public requests a public hearing during the 30-day comment period, the hearing shall be held prior to the adoption of the regulations. If no member of the public requests a public hearing, the regulations shall be deemed adopted at the conclusion of the 30-day comment period. Comments received shall be considered prior to the adoption of the final initial regulations. The department may modify any guidance published by the American Society for Reproductive Medicine. Adoption of initial regulations by the department pursuant to this subdivision shall not be subject to the rulemaking requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code and written responses to public comments shall not be required. Updates to the regulations shall be adopted pursuant to the same process. Until the department adopts these regulations, facilities that perform sperm processing pursuant to this section shall follow facility and sperm processing guidelines for the reduction of viral transmission developed by the American Society for Reproductive Medicine. Nothing in this section shall prevent the department from monitoring and inspecting facilities that process sperm to ensure adherence to the regulations, or, until regulations are adopted, to the guidelines set forth by the American Society for Reproductive Medicine.
(iii)Prior to insemination or other assisted reproductive technology services, the physician providing the services shall inform the recipient of sperm from a spouse, partner, or designated donor who has tested reactive for HIV or HTLV of all of the following:
(I)That sperm processing may not eliminate all of the risks of HIV or HTLV transmission.
(II)That the sperm may be tested to determine whether or not it is reactive for HIV or HTLV.
(III)That the recipient must provide documentation to the physician providing insemination or assisted reproductive technology services prior to treatment that she has established an ongoing relationship with another physician to provide for her medical care during and after completion of fertility services.
(IV)The recommendations made within the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine regarding followup testing for HIV and HTLV after use of sperm from an HIV or HTLV reactive donor and have the recommendations regarding followup testing be documented in the recipients medical record.
(iv)The physician providing insemination or assisted reproductive technology services shall also verify, and document in the recipients medical record, that the donor of sperm who tests reactive for HIV or HTLV is under the care of a physician managing the HIV or HTLV.
(v)The physician providing insemination or assisted reproductive technology services shall recommend to the physician who will be providing ongoing care to the recipient recommended followup testing for HIV and HTLV according to the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine, which shall be documented in the recipients medical record.
(vi)If the recipient becomes HIV or HTLV positive, the physician assuming ongoing care of the recipient shall treat or provide information regarding referral to a physician who can provide ongoing treatment of the HIV or HTLV.
(4)A recipient of sperm donated by a sexually intimate partner of the recipient for reproductive use may waive a second or repeat testing of that donor if the recipient is informed of the donor testing requirements of this section and signs a written waiver. For purposes of this paragraph, sexually intimate partner of the recipient includes a known or designated donor to whose sperm the recipient has previously been exposed in a nonmedical setting in an attempt to conceive.
(d)Subdivision (a) shall not apply to the transplantation of tissue from a donor who has not been tested or, with the exception of HTLV, has been found reactive for the infectious diseases listed in subdivision (a) or for which the department has, by regulation, required additional screening tests, if all of the following conditions are satisfied:
(1)The physician and surgeon performing the transplantation has determined any one or more of the following:
(A)Without the transplantation the intended recipient will most likely die during the period of time necessary to obtain other tissue or to conduct the required tests.
(B)The intended recipient already is diagnosed with the infectious disease for which the donor has tested positive.
(C)The symptoms from the infectious disease for which the donor has tested positive will most likely not appear during the intended recipients likely lifespan after transplantation with the tissue or may be treated prophylactically if they do appear.
(2)The physician and surgeon performing the transplantation has ensured that tissue an organ from an individual who has been found reactive for HIV may be transplanted only into an individual who satisfies both of the following:
(A)The individual has been found reactive for HIV before receiving the tissue. organ.
(B)The individual is either participating in clinical research approved by an institutional review board under the criteria, standards, and regulations described in subsections (a) and (b) of Section 274f-5 of Title 42 of the United States Code, or, if the United States Secretary of Health and Human Services determines under subsection (c) of Section 274f-5 of Title 42 of the United States Code that participation in this clinical research is no longer warranted as a requirement for transplants, the individual is receiving the transplant under the standards and regulations under subsection (c) of Section 274f-5 of Title 42 of the United States Code.
(3)Consent for the use of the tissue has been obtained from the recipient, if possible, or if not possible, from a member of the recipients family, or the recipients legal guardian. For purposes of this section, family shall mean spouse, adult son or daughter, either parent, adult brother or sister, or grandparent.
(e)The penalties prescribed in Sections 1621.5 and 120290 do not apply to a sperm donor covered under subdivision (c) or a tissue donor covered under subdivision (d). (c) or an organ donor who donates an organ for transplantation or research purposes.
(f)Human breast milk from donors who test reactive for agents of viral hepatitis (HBV and HCV), HTLV, HIV, or syphilis shall not be used for deposit into a milk bank for human ingestion in California.
SEC. 6.Section 120290 of the Health and Safety Code is amended to read:120290.(a)Except as provided in Section 120291 or in the case of the removal of an afflicted person in a manner the least dangerous to the public health, any person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, and any person who willfully exposes another person afflicted with the disease to someone else, is guilty of a misdemeanor.
(b)This section shall not apply to a person who donates an organ for transplantation or research purposes.
(a)Except as provided in subdivision (c) or (d), no tissues shall be transferred into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive by laboratory tests for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), and syphilis. For tissues that are rich in viable leukocytes, the tissue shall be tested for evidence of infection with human T lymphotropic virus (HTLV) and found nonreactive. The department may adopt regulations requiring additional screening tests of donors of tissues when, in the opinion of the department, the action is necessary for the protection of the public, donors, or recipients.
(b)Notwithstanding subdivision (a), infectious disease screening of blood and blood products shall be carried out solely in accordance with Article 2 (commencing with Section 1602.5) of Chapter 4.
(c)All donors of sperm shall be screened and found nonreactive as required under subdivision (a), except in the following instances:
(1)A recipient of sperm, from a sperm donor known to the recipient, may waive a second or other repeat testing of that donor if the recipient is informed of the requirements for testing donors under this section and signs a written waiver.
(2)A recipient of sperm may consent to therapeutic insemination of sperm or use of sperm in other assisted reproductive technologies even if the sperm donor is found reactive for hepatitis B, hepatitis C, syphilis, HIV, or HTLV if the sperm donor is the spouse of, partner of, or designated donor for that recipient. The physician providing insemination or assisted reproductive technology services shall advise the donor and recipient of the potential medical risks associated with receiving sperm from a reactive donor. The donor and the recipient shall sign a document affirming that each comprehends the potential medical risks of using sperm from a reactive donor for the proposed procedure and that each consents to it. Copies of the document shall be placed in the medical records of the donor and the recipient.
(3)(A)Sperm whose donor has tested reactive for syphilis may be used for the purposes of insemination or assisted reproductive technology only after the donor has been treated for syphilis. Sperm whose donor has tested reactive for hepatitis B may be used for the purposes of insemination or assisted reproductive technology only after the recipient has been vaccinated against hepatitis B.
(B)(i)Sperm whose donor has tested reactive for HIV or HTLV may be used for the purposes of insemination or assisted reproductive technology for a recipient testing negative for HIV or HTLV only after the donors sperm has been effectively processed to minimize the infectiousness of the sperm for that specific donation and where informed and mutual consent has occurred.
(ii)The department shall adopt regulations regulating facilities that perform sperm processing, pursuant to this subparagraph, that prescribe standards for the handling and storage of sperm samples of carriers of HIV, HTLV, or any other virus as deemed appropriate by the department. The department may propose to adopt, as initial regulations, the recommendations made within the Guidelines for Reducing Risk of Viral Transmission During Fertility Treatment as published by the American Society for Reproductive Medicine. Notice of the departments proposed adoption of the regulations shall be posted on the departments Internet Web site for at least 45 days. Public comment shall be accepted by the department for at least 30 days after the conclusion of the 45-day posting period. If a member of the public requests a public hearing during the 30-day comment period, the hearing shall be held prior to the adoption of the regulations. If no member of the public requests a public hearing, the regulations shall be deemed adopted at the conclusion of the 30-day comment period. Comments received shall be considered prior to the adoption of the final initial regulations. The department may modify any guidance published by the American Society for Reproductive Medicine. Adoption of initial regulations by the department pursuant to this subdivision shall not be subject to the rulemaking requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code and written responses to public comments shall not be required. Updates to the regulations shall be adopted pursuant to the same process. Until the department adopts these regulations, facilities that perform sperm processing pursuant to this section shall follow facility and sperm processing guidelines for the reduction of viral transmission developed by the American Society for Reproductive Medicine. Nothing in this section shall prevent the department from monitoring and inspecting facilities that process sperm to ensure adherence to the regulations, or, until regulations are adopted, to the guidelines set forth by the American Society for Reproductive Medicine.
(iii)Prior to insemination or other assisted reproductive technology services, the physician providing the services shall inform the recipient of sperm from a spouse, partner, or designated donor who has tested reactive for HIV or HTLV of all of the following:
(I)That sperm processing may not eliminate all of the risks of HIV or HTLV transmission.
(II)That the sperm may be tested to determine whether or not it is reactive for HIV or HTLV.
(III)That the recipient must provide documentation to the physician providing insemination or assisted reproductive technology services prior to treatment that she has established an ongoing relationship with another physician to provide for her medical care during and after completion of fertility services.
(IV)The recommendations made within the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine regarding followup testing for HIV and HTLV after use of sperm from an HIV or HTLV reactive donor and have the recommendations regarding followup testing be documented in the recipients medical record.
(iv)The physician providing insemination or assisted reproductive technology services shall also verify, and document in the recipients medical record, that the donor of sperm who tests reactive for HIV or HTLV is under the care of a physician managing the HIV or HTLV.
(v)The physician providing insemination or assisted reproductive technology services shall recommend to the physician who will be providing ongoing care to the recipient recommended followup testing for HIV and HTLV according to the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine, which shall be documented in the recipients medical record.
(vi)If the recipient becomes HIV or HTLV positive, the physician assuming ongoing care of the recipient shall treat or provide information regarding referral to a physician who can provide ongoing treatment of the HIV or HTLV.
(4)A recipient of sperm donated by a sexually intimate partner of the recipient for reproductive use may waive a second or repeat testing of that donor if the recipient is informed of the donor testing requirements of this section and signs a written waiver. For purposes of this paragraph, sexually intimate partner of the recipient includes a known or designated donor to whose sperm the recipient has previously been exposed in a nonmedical setting in an attempt to conceive.
(d)Subdivision (a) shall not apply to the transplantation of tissue from a donor who has not been tested or, with the exception of HTLV, has been found reactive for the infectious diseases listed in subdivision (a) or for which the department has, by regulation, required additional screening tests, if both all of the following conditions are satisfied:
(1)The physician and surgeon performing the transplantation has determined any one or more of the following:
(A)Without the transplantation the intended recipient will most likely die during the period of time necessary to obtain other tissue or to conduct the required tests.
(B)The intended recipient already is diagnosed with the infectious disease for which the donor has tested positive.
(C)The symptoms from the infectious disease for which the donor has tested positive will most likely not appear during the intended recipients likely lifespan after transplantation with the tissue or may be treated prophylactically if they do appear.
(2)The physician and surgeon performing the transplantation has ensured that tissue from an individual who has been found reactive for HIV may be transplanted only into an individual who satisfies both of the following:
(A)The individual has been found reactive for HIV before receiving the tissue.
(B)The individual is either participating in clinical research approved by an institutional review board under the criteria, standards, and regulations described in subsections (a) and (b) of Section 274f-5 of Title 42 of the United States Code, or, if the United States Secretary of Health and Human Services determines under subsection (c) of Section 274f-5 of Title 42 of the United States Code that participation in this clinical research is no longer warranted as a requirement for transplants, the individual is receiving the transplant under the standards and regulations under subsection (c) of Section 274f-5 of Title 42 of the United States Code.
(2)
(3)Consent for the use of the tissue has been obtained from the recipient, if possible, or if not possible, from a member of the recipients family, or the recipients legal guardian. For purposes of this section, family shall mean spouse, adult son or daughter, either parent, adult brother or sister, or grandparent.
(e)The penalties of prescribed in Sections 1621.5 and 120290 do not apply to a sperm donor covered under subdivision (c) or a tissue donor covered under subdivision (d).
(f)Human breast milk from donors who test reactive for agents of viral hepatitis (HBV and HCV), HTLV, HIV, or syphilis shall not be used for deposit into a milk bank for human ingestion in California.
(a)Except as provided in subdivision (c) or (d), no tissues shall be transferred into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive by laboratory tests for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), and syphilis. For tissues that are rich in viable leukocytes, the tissue shall be tested for evidence of infection with human T lymphotropic virus (HTLV) and found nonreactive. The department may adopt regulations requiring additional screening tests of donors of tissues when, in the opinion of the department, the action is necessary for the protection of the public, donors, or recipients.
(b)Notwithstanding subdivision (a), infectious disease screening of blood and blood products shall be carried out solely in accordance with Article 2 (commencing with Section 1602.5) of Chapter 4.
(c)All donors of sperm shall be screened and found nonreactive as required under subdivision (a), except in the following instances:
(1)A recipient of sperm, from a sperm donor known to the recipient, may waive a second or other repeat testing of that donor if the recipient is informed of the requirements for testing donors under this section and signs a written waiver.
(2)A recipient of sperm may consent to therapeutic insemination of sperm or use of sperm in other assisted reproductive technologies even if the sperm donor is found reactive for hepatitis B, hepatitis C, syphilis, HIV, or HTLV if the sperm donor is the spouse of, partner of, or designated donor for that recipient. The physician providing insemination or assisted reproductive technology services shall advise the donor and recipient of the potential medical risks associated with receiving sperm from a reactive donor. The donor and the recipient shall sign a document affirming that each comprehends the potential medical risks of using sperm from a reactive donor for the proposed procedure and that each consents to it. Copies of the document shall be placed in the medical records of the donor and the recipient.
(3)(A)Sperm whose donor has tested reactive for syphilis may be used for the purposes of insemination or assisted reproductive technology only after the donor has been treated for syphilis. Sperm whose donor has tested reactive for hepatitis B may be used for the purposes of insemination or assisted reproductive technology only after the recipient has been vaccinated against hepatitis B.
(B)(i)Sperm whose donor has tested reactive for HIV or HTLV may be used for the purposes of insemination or assisted reproductive technology for a recipient testing negative for HIV or HTLV only after the donors sperm has been effectively processed to minimize the infectiousness of the sperm for that specific donation and where informed and mutual consent has occurred.
(ii)The department shall adopt regulations regulating facilities that perform sperm processing, pursuant to this subparagraph, that prescribe standards for the handling and storage of sperm samples of carriers of HIV, HTLV, or any other virus as deemed appropriate by the department. The department may propose to adopt, as initial regulations, the recommendations made within the Guidelines for Reducing Risk of Viral Transmission During Fertility Treatment as published by the American Society for Reproductive Medicine. Notice of the departments proposed adoption of the regulations shall be posted on the departments Internet Web site for at least 45 days. Public comment shall be accepted by the department for at least 30 days after the conclusion of the 45-day posting period. If a member of the public requests a public hearing during the 30-day comment period, the hearing shall be held prior to the adoption of the regulations. If no member of the public requests a public hearing, the regulations shall be deemed adopted at the conclusion of the 30-day comment period. Comments received shall be considered prior to the adoption of the final initial regulations. The department may modify any guidance published by the American Society for Reproductive Medicine. Adoption of initial regulations by the department pursuant to this subdivision shall not be subject to the rulemaking requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code and written responses to public comments shall not be required. Updates to the regulations shall be adopted pursuant to the same process. Until the department adopts these regulations, facilities that perform sperm processing pursuant to this section shall follow facility and sperm processing guidelines for the reduction of viral transmission developed by the American Society for Reproductive Medicine. Nothing in this section shall prevent the department from monitoring and inspecting facilities that process sperm to ensure adherence to the regulations, or, until regulations are adopted, to the guidelines set forth by the American Society for Reproductive Medicine.
(iii)Prior to insemination or other assisted reproductive technology services, the physician providing the services shall inform the recipient of sperm from a spouse, partner, or designated donor who has tested reactive for HIV or HTLV of all of the following:
(I)That sperm processing may not eliminate all of the risks of HIV or HTLV transmission.
(II)That the sperm may be tested to determine whether or not it is reactive for HIV or HTLV.
(III)That the recipient must provide documentation to the physician providing insemination or assisted reproductive technology services prior to treatment that she has established an ongoing relationship with another physician to provide for her medical care during and after completion of fertility services.
(IV)The recommendations made within the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine regarding followup testing for HIV and HTLV after use of sperm from an HIV or HTLV reactive donor and have the recommendations regarding followup testing be documented in the recipients medical record.
(iv)The physician providing insemination or assisted reproductive technology services shall also verify, and document in the recipients medical record, that the donor of sperm who tests reactive for HIV or HTLV is under the care of a physician managing the HIV or HTLV.
(v)The physician providing insemination or assisted reproductive technology services shall recommend to the physician who will be providing ongoing care to the recipient recommended followup testing for HIV and HTLV according to the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine, which shall be documented in the recipients medical record.
(vi)If the recipient becomes HIV or HTLV positive, the physician assuming ongoing care of the recipient shall treat or provide information regarding referral to a physician who can provide ongoing treatment of the HIV or HTLV.
(4)A recipient of sperm donated by a sexually intimate partner of the recipient for reproductive use may waive a second or repeat testing of that donor if the recipient is informed of the donor testing requirements of this section and signs a written waiver. For purposes of this paragraph, sexually intimate partner of the recipient includes a known or designated donor to whose sperm the recipient has previously been exposed in a nonmedical setting in an attempt to conceive.
(d)Subdivision (a) shall not apply to the transplantation of tissue from a donor who has not been tested or, with the exception of HTLV, has been found reactive for the infectious diseases listed in subdivision (a) or for which the department has, by regulation, required additional screening tests, if both of the following conditions are satisfied:
(1)The physician and surgeon performing the transplantation has determined any one or more of the following:
(A)Without the transplantation the intended recipient will most likely die during the period of time necessary to obtain other tissue or to conduct the required tests.
(B)The intended recipient already is diagnosed with the infectious disease for which the donor has tested positive.
(C)The symptoms from the infectious disease for which the donor has tested positive will most likely not appear during the intended recipients likely lifespan after transplantation with the tissue or may be treated prophylactically if they do appear.
(2)Consent for the use of the tissue has been obtained from the recipient, if possible, or if not possible, from a member of the recipients family, or the recipients legal guardian. For purposes of this section, family shall mean spouse, adult son or daughter, either parent, adult brother or sister, or grandparent.
(e)The penalties of Section prescribed in Sections 1621.5 shall and 120290 do not apply to a sperm donor covered under subdivision (c). (c) or a tissue donor covered under subdivision (d).
(f)Human breast milk from donors who test reactive for agents of viral hepatitis (HBV and HCV), HTLV, HIV, or syphilis shall not be used for deposit into a milk bank for human ingestion in California.
(a)Except as provided in subdivision (c) or (d), no tissues shall be transferred into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive by laboratory tests for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), and syphilis. For tissues that are rich in viable leukocytes, the tissue shall be tested for evidence of infection with human T lymphotrophic virus (HTLV) and found nonreactive. The department may adopt regulations requiring additional screening tests of donors of tissues when, in the opinion of the department, the action is necessary for the protection of the public, donors, or recipients.
(b)Notwithstanding subdivision (a), infectious disease screening of blood and blood products shall be carried out solely in accordance with Article 2 (commencing with Section 1602.5) of Chapter 4.
(c)All donors of sperm shall be screened and found nonreactive as required under subdivision (a), except in the following instances:
(1)A recipient of sperm, from a sperm donor known to the recipient, may waive a second or other repeat testing of that donor if the recipient is informed of the requirements for testing donors under this section and signs a written waiver.
(2)A recipient of sperm may consent to therapeutic insemination of sperm or use of sperm in other assisted reproductive technologies even if the sperm donor is found reactive for hepatitis B, hepatitis C, syphilis, HIV, or HTLV if the sperm donor is the spouse of, partner of, or designated donor for that recipient. The physician providing insemination or assisted reproductive technology services shall advise the donor and recipient of the potential medical risks associated with receiving sperm from a reactive donor. The donor and the recipient shall sign a document affirming that each comprehends the potential medical risks of using sperm from a reactive donor for the proposed procedure and that each consents to it. Copies of the document shall be placed in the medical records of the donor and the recipient.
(3)(A)Sperm whose donor has tested reactive for syphilis may be used for the purposes of insemination or assisted reproductive technology only after the donor has been treated for syphilis. Sperm whose donor has tested reactive for hepatitis B may be used for the purposes of insemination or assisted reproductive technology only after the recipient has been vaccinated against hepatitis B.
(B)(i)Sperm whose donor has tested reactive for HIV or HTLV may be used for the purposes of insemination or assisted reproductive technology for a recipient testing negative for HIV or HTLV only after the donors sperm has been effectively processed to minimize the infectiousness of the sperm for that specific donation and where informed and mutual consent has occurred.
(ii)Not later than January 1, 2014, the The department shall adopt regulations regulating facilities that perform sperm processing, pursuant to this subparagraph, that prescribe standards for the handling and storage of sperm samples of carriers of HIV, HTLV, or any other virus as deemed appropriate by the department. The department may propose to adopt, as initial regulations, the recommendations made within the Guidelines for Reducing Risk of Viral Transmission During Fertility Treatment as published by the American Society for Reproductive Medicine. Notice of the departments proposed adoption of the regulations shall be posted on the departments Internet Web site for at least 45 days. Public comment shall be accepted by the department for at least 30 days after the conclusion of the 45-day posting period. If a member of the public requests a public hearing during the 30-day comment period, the hearing shall be held prior to the adoption of the regulations. If no member of the public requests a public hearing, the regulations shall be deemed adopted at the conclusion of the 30-day comment period. Comments received shall be considered prior to the adoption of the final initial regulations. The department may modify any guidance published by the American Society for Reproductive Medicine. Adoption of initial regulations by the department pursuant to this subdivision shall not be subject to the rulemaking requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code and written responses to public comments shall not be required. Updates to the regulations shall be adopted pursuant to the same process. Until the department adopts these regulations, facilities that perform sperm processing pursuant to this section shall follow facility and sperm processing guidelines for the reduction of viral transmission developed by the American Society for Reproductive Medicine. Nothing in this section shall prevent the department from monitoring and inspecting facilities that process sperm to ensure adherence to the regulations, or, until regulations are adopted, to the guidelines set forth by the American Society for Reproductive Medicine.
(iii)Prior to insemination or other assisted reproductive technology services, the physician providing the services shall inform the recipient of sperm from a spouse, partner, or designated donor who has tested reactive for HIV or HTLV of all of the following:
(I)That sperm processing may not eliminate all of the risks of HIV or HTLV transmission.
(II)That the sperm may be tested to determine whether or not it is reactive for HIV or HTLV.
(III)That the recipient must provide documentation to the physician providing insemination or assisted reproductive technology services prior to treatment that she has established an ongoing relationship with another physician to provide for her medical care during and after completion of fertility services.
(IV)The recommendations made within the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine regarding followup testing for HIV and HTLV after use of sperm from an HIV or HTLV reactive donor and have the recommendations regarding followup testing be documented in the recipients medical record.
(iv)The physician providing insemination or assisted reproductive technology services shall also verify, and document in the recipients medical record, that the donor of sperm who tests reactive for HIV or HTLV is under the care of a physician managing the HIV or HTLV.
(v)The physician providing insemination or assisted reproductive technology services shall recommend to the physician who will be providing ongoing care to the recipient recommended followup testing for HIV and HTLV according to the Guidelines for Reducing the Risk of Viral Transmission During Fertility Treatment published by the American Society for Reproductive Medicine, which shall be documented in the recipients medical record.
(vi)In the event that If the recipient becomes HIV or HTLV positive, the physician assuming ongoing care of the recipient shall treat or provide information regarding referral to a physician who can provide ongoing treatment of the HIV or HTLV.
(4)A recipient of sperm donated by a sexually intimate partner of the recipient for reproductive use may waive a second or repeat testing of that donor if the recipient is informed of the donor testing requirements of this section and signs a written waiver. For purposes of this paragraph, sexually intimate partner of the recipient includes a known or designated donor to whose sperm the recipient has previously been exposed in a nonmedical setting in an attempt to conceive.
(d)Subdivision (a) shall not apply to the transplantation of tissue from a donor who has not been tested or, with the exception of HIV and HTLV, has been found reactive for the infectious diseases listed in subdivision (a) or for which the department has, by regulation, required additional screening tests, if both of the following conditions are satisfied:
(1)The physician and surgeon performing the transplantation has determined any one or more of the following:
(A)Without the transplantation the intended recipient will most likely die during the period of time necessary to obtain other tissue or to conduct the required tests.
(B)The intended recipient already is diagnosed with the infectious disease for which the donor has tested positive.
(C)The symptoms from the infectious disease for which the donor has tested positive will most likely not appear during the intended recipients likely lifespan after transplantation with the tissue or may be treated prophylactically if they do appear.
(2)Consent for the use of the tissue has been obtained from the recipient, if possible, or if not possible, from a member of the recipients family, or the recipients legal guardian. For purposes of this section, family shall mean spouse, adult son or daughter, either parent, adult brother or sister, or grandparent.
(e)The penalties of Section 1621.5 shall not apply to a sperm donor covered under subdivision (c).
(f)Human breast milk from donors who test reactive for agents of viral hepatitis (HBV and HCV), HTLV, HIV, or syphilis shall not be used for deposit into a milk bank for human ingestion in California.
SECTION 1.Section 125285.5 of the Health and Safety Code is amended to read:125285.5.(a)The Legislature finds and declares all of the following:
(1)It is estimated that there are between 60,000 and 85,000 people with dementia in Californias Coordinated Care Initiative.
(2)Average per person Medicaid spending for seniors who are dually eligible for Medicare and who have Alzheimers disease and other dementias is 19 times higher than average per person Medicaid spending for all other seniors.
(3)The triple aim of the federal Patient Protection and Affordable Care Act (Public Law 111-148) and Medicaid expansion is improved population health, better experience of care, and lower per capita health care costs.
(4)Dementia care management has been proven, through peer-reviewed, evidence-based research, to achieve all three aims.
(b)The State Department of Public Health shall convene a workgroup to update the 2008 Guidelines for Alzheimers Disease Management in California to address changes in the health care system, including, but not limited to, changes in the federal Patient Protection and Affordable Care Act (Public Law 111-148), Medicaid, and Medicare. In updating the guidelines, the workgroup may draw on evidence-based, peer-reviewed research and lessons learned from demonstration and pilot projects.
(c)The workgroup shall consist of members determined by the department. It may include multidisciplinary experts in Alzheimers disease detection, diagnosis, treatment, and support.
(d)The department shall submit a report of the updates and recommendations from the working group to the Legislature on or before March 1, 2017. This report shall be submitted in compliance with Section 9795 of the Government Code.
(e)This section shall remain in effect only until January 1, 2018, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2018, deletes or extends that date.
(a)The Legislature finds and declares all of the following:
(1)There It is estimated that there are between an estimated 60,000 to and 85,000 people with dementia in Californias Coordinated Care Initiative.
(2)Average per person Medicaid spending for seniors who are dually eligible for Medicare with and who have Alzheimers disease and other dementias is 19 times higher than average per person Medicaid spending for all other seniors.
(3)The triple aim of the federal Patient Protection and Affordable Care Act (Public Law 111-148) and Medicaid expansion is improved population health, better experience of care, and lower per capita health care costs.
(4)Dementia care management has been proven, through peer-reviewed, evidence-based research, to achieve all three aims.
(b)The State Department of Public Health shall convene a workgroup to update the 2008 Guidelines for Alzheimers Disease Management in California to address changes in the health care system, including, but not limited to, changes in the federal Patient Protection and Affordable Care Act (Public Law 111-148), Medicaid, and Medicare. In updating the guidelines, the workgroup may draw on evidence-based, peer-reviewed research and lessons learned from demonstration and pilot projects.
(c)The workgroup shall consist of members determined by the department. It may include multidisciplinary experts in Alzheimers disease detection, diagnosis, treatment, and support.
(d)The department shall submit a report of the updates and recommendations from the working group to the Legislature on or before March 1, 2017. This report shall be submitted in compliance with Section 9795 of the Government Code.
(e)This section shall remain in effect only until January 1, 2018, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2018, deletes or extends that date.
|
Date
|
Status
|
|---|---|
| May 27, 2016 | Read third time. Urgency clause adopted. Passed. (Ayes 72. Noes 0. Page 4946.) Ordered to the Senate. |
| May 27, 2016 | Assembly amendments concurred in. (Ayes 38. Noes 0. Page 3975.) Ordered to engrossing and enrolling. |
| May 27, 2016 | Chaptered by Secretary of State. Chapter 18, Statutes of 2016. |
| May 27, 2016 | Approved by the Governor. |
| May 27, 2016 | Assembly Rule 63 suspended. |
| May 27, 2016 | Read second time. Ordered to third reading. |
| May 27, 2016 | Enrolled and presented to the Governor at 12:30 p.m. |
| May 27, 2016 | Assembly amendments concurred in. (Ayes 38. Noes 0.) Ordered to engrossing and enrolling. |
| May 27, 2016 | Urgency clause adopted. |
| May 27, 2016 | Unanimous consent granted to take up without reference to file. |
| May 27, 2016 | In Senate. Concurrence in Assembly amendments pending. |
| May 27, 2016 | Read third time. Urgency clause adopted. Passed. Ordered to the Senate. |
| May 26, 2016 | Read second time and amended. Ordered to second reading. |
| May 25, 2016 | From committee: Do pass as amended. (Ayes 15. Noes 0.) (May 25). |
| May 23, 2016 | Joint Rule 62(a) suspended. (Page 4886.) |
| May 23, 2016 | Joint Rule 61(b) suspended. (Ayes 74. Noes 0. Page 4886.) |
| May 23, 2016 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| May 23, 2016 | Joint Rule 62(a) suspended. |
| May 23, 2016 | Joint Rule 61(b) suspended. |
| May 23, 2016 | Referred to Com. on HEALTH. |
| May 16, 2016 | Read third time. Passed. (Ayes 34. Noes 0. Page 3871.) Ordered to the Assembly. |
| May 16, 2016 | In Assembly. Read first time. Held at Desk. |
| May 16, 2016 | Read third time. Passed. (Ayes 34. Noes 0.) Ordered to the Assembly. |
| May 4, 2016 | Read second time and amended. Ordered to third reading. |
| May 3, 2016 | From committee: Do pass as amended. (Ayes 8. Noes 0. Page 3725.) (April 27). |
| May 3, 2016 | From committee: Do pass as amended. (Ayes 8. Noes 0.) (April 27). |
| Apr 18, 2016 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Apr 13, 2016 | Set for hearing April 27. |
| Apr 12, 2016 | April 20 set for first hearing canceled at the request of author. |
| Apr 12, 2016 | Set for hearing April 20. |
| Apr 7, 2016 | Re-referred to Com. on HEALTH. |
| Apr 4, 2016 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on RLS. |
| Mar 10, 2016 | Referred to Com. on RLS. |
| Feb 22, 2016 | Read first time. |
| Feb 22, 2016 | From printer. May be acted upon on or after March 23. |
| Feb 19, 2016 | Introduced. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| May 27, 2016 | SB 1408 Allen Third Reading Urgency By WOOD | Assembly Floor |
Passed |
|
| May 27, 2016 | W/O REF. TO FILE SB1408 Allen Urgency Clause Concurrence | Senate Floor |
Passed |
|
| May 25, 2016 | Do pass as amended. | Assembly Standing Committee on Health |
Passed |
|
| May 16, 2016 | Senate 3rd Reading SB1408 Allen | Senate Floor |
Passed |
|
| Apr 27, 2016 | Do pass as amended | Senate Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
(Without Reference to File)
SENATE THIRD READING
STR Bill Id:SB 1408
Author:(Allen)
As Amended Ver:May 26, 2016
2/3 vote. Urgency
SENATE VOTE: 34-0
Committee | Votes | Ayes | Noes |
Health | 15-0 | Wood, Maienschein, Gordon, Burke, Campos, Chiu, Gomez, Lackey, Nazarian, Olsen, Jones, Rodriguez, Santiago, Thurmond, Waldron |
|
SUMMARY: Allows for the transplantation of organs into the body of a person when the donor of the organ has human immunodeficiency virus (HIV). Contains an urgency clause to ensure that the provisions of this bill go into immediate effect upon enactment. Specifically, this bill:
- Deletes the prohibition in existing law on the transplantation of tissue from a donor with HIV and instead permits such transplantation if the physician and surgeon performing the transplantation has ensured that the organ from an individual who has been found reactive to HIV may be transplanted only into an individual who satisfies both of the following:
- The individual has been found reactive for HIV before receiving the organ; and,
- The individual is either participating in clinical research approved by an institutional review board pursuant to federal requirements, or if the United States (U.S.) Secretary of Health and Human Services determines that participation in this clinical research is no longer warranted as a requirement for transplants, as specified.
- Exempts the donation of organs from HIV positive individuals from specified criminal penalties.
- Defines "organ," for purposes of this bill, as a human kidney, liver, heart, lung, pancreas, or intestine (including the esophagus, stomach, small or large intestine, or any portion of the gastrointestinal tract), or vascularized composite allograft, and associated blood vessels recovered from an organ donor during the recovery of such organ.
- Provides that the Medical Board of California will not take disciplinary action against a licensee who performs organ transplants in compliance with this bill.
FISCAL EFFECT: None.
COMMENTS: According to the author this bill would greatly improve the life expectancies of people living with HIV who need organ transplants by removing California's prohibition on donating organs while HIV-positive. The author notes that under current state law, it is illegal for an HIV-positive person to donate organs under any circumstance. The author points out this law was enacted nearly 20 years ago at a time when very little was known about HIV and acquired immune deficiency syndrome (AIDS), and that recent research made possible by the passage of the federal HIV Organ Policy Equity (HOPE) Act of 2013 found that organ donations from HIV-positive donors to HIV-positive recipients are safe. The author continues, major advances in the treatment of HIV and AIDS mean that HIV-positive individuals are living longer, and like other older Americans, they too are developing medical conditions that require organ transplants. However, the number of individuals in need of organ transplants far exceeds the availability of healthy organs and increasing the number of eligible donors for HIV-positive individuals will save lives.
According to an article published in September of 1987 in the journal Transfusion, an estimated 12,000 people in the U.S. contracted HIV from blood transfusions between 1978 and 1984, leaving the public fearful. In response, the U.S. passed a ban on organ collection from HIV-positive donors in 1988. However, by the late 1990s screening procedures for HIV had become accurate enough to eliminate this worry, and simultaneously, the development of effective antiretroviral drugs meant that HIV-infected people could expect to live to a relatively old age, and also develop the disorders that come with advancing age.
In 1999 the University of California, San Francisco (UCSF) transplant surgeon, Dr. Peter Stock received a $3 million grant from the state of California for a pilot study transplanting uninfected livers and kidneys into HIV-positive recipients. The 37 patients appeared to do well overall and were only slightly more likely to reject organs than HIV-negative recipients were. In 2004, Dr. Stock and his colleagues published an article in the New England Journal of Medicine, "Outcomes of Kidney Transplantation in HIV-Infected Recipients." The article discussed the results of another trial in which 150 patients underwent kidney transplants between November 2003 and June 2009. According to the article, the trial showed that kidney transplantation appears to be a feasible therapy in carefully selected HIV-infected patients.
On November 21, 2013, President Obama signed into law the HOPE Act, which allowed for scientists to carry out research into organ donations from one person with HIV to another.
A March 30, 2016, article in the Los Angeles Times announced the first organ transplantation from a deceased HIV-positive donor to two HIV-positive recipients in the U.S., performed by surgeons at Johns Hopkins University Medical Center in Baltimore Maryland. The surgeons who performed the transplants at Johns Hopkins conducted research, published in The American Journal of Transplantation in 2011 that each year 500 to 600 HIV-positive people will die under circumstances that would make their organs available for transplant, which has the potential to save about 1,000 lives each year.
Currently there are four hospitals who have met the criteria to participate in HOPE Act transplant research: Johns Hopkins Hospital in Baltimore, Maryland (liver and kidney programs), Hahnemann University Hospital in Philadelphia, Pennsylvania (liver and kidney programs), Mount Sinai Medical Center in New York, New York (liver and kidney programs), and UCSF Medical Center, San Francisco, California (liver {deceased and living donor} and kidney {deceased donor} programs).
According to the Organ Procurement and Transplantation Network there are currently 123,288 people in the U.S. waiting for a life-saving organ transplant, and every 10 minutes another person is added to that list. Each day an average of 22 patients die waiting for an organ. According to the United Network for Organ Sharing, approximately 23,000 Californians are on the waiting list for an organ transplant.
Analysis Prepared by: Lara Flynn / HEALTH / (916) 319-2097 FN: 0003057
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB |
UNFINISHED BUSINESS
Bill No: SB 1408
:
SENATE HEALTH COMMITTEE: 8-0, 4/27/16
AYES: Hernandez, Nguyen, Mitchell, Monning, Nielsen, Pan, Roth, Wolk
NO VOTE RECORDED: Hall
SENATE FLOOR: 34-0, 5/16/16
AYES: Allen, Anderson, Bates, Beall, Berryhill, Block, Cannella, De León, Fuller, Gaines, Galgiani, Glazer, Hernandez, Hertzberg, Hill, Huff, Jackson, Lara, Leno, Leyva, Liu, McGuire, Mitchell, Monning, Moorlach, Morrell, Nguyen, Nielsen, Pavley, Roth, Stone, Vidak, Wieckowski, Wolk
NO VOTE RECORDED: Hall, Hancock, Hueso, Mendoza, Pan, Runner
ASSEMBLY FLOOR: Not available
SOURCE: AIDS Project Los Angeles
Equality California
Los Angeles LGBT Center
Positive Women’s Network—USA
DIGEST: This bill allows for the transplantation of organs into the body of a person, as specified, when the donor of the organs is found reactive for human immunodeficiency virus (HIV), and removes penalties for organ donors who are found reactive to HIV, as specified.
Assembly Amendments:
- Narrow this bill to apply to the transplantation of organs, as defined, between donors and recipients who are found to be reactive for HIV.
- Define “organ” for purposes of organ transplantation and research purposes in compliance with the federal HIV Organ Policy Equity (HOPE) Act, as specified.
- Exempt from tissue bank licensure the collection, processing, storage, or distribution of any organ, as specified, within a single general acute care hospital, as defined, operating a Medicare-approved transplant program.
- Add a provision to prohibit disciplinary action by the Medical Board of California (MBC) against a licensee who performs organ transplants within the standard of care and in compliance with this bill.
- Add an urgency clause for this bill to take effect immediately in order to provide for organ donations and transplants to occur at the earliest opportunity.
- Add coauthors.
Existing law:
- Prohibits the transfer of any tissues, as defined, into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive for evidence of infection with HIV, agents of viral hepatitis (HBV and HCV), human T lymphotropic virus (HTLV), and syphilis, except as provided.
- Authorizes the transplantation of tissue from a donor who has not been tested for specified infectious diseases or, with the exception of HIV and HTLV, has been found reactive, if specified conditions are satisfied, including obtaining consent from an intended recipient or the recipient’s family. Defines “family” as a spouse, adult son or daughter, either parent, adult brother or sister, or grandparent.
This bill:
- Allows for the transplantation of organs into the body of a person who is found to be reactive for HIV when the donor of the organs is also found reactive for HIV and both of the following conditions are satisfied:
- The individual receiving the organs has been found reactive for HIV before receiving the organ.
- The individual is either participating in clinical research approved by an institutional review board under the criteria, standards, and regulations described in subsections (a) and (b) of Section 274f-5 of Title 42 of the United States Code (USC), or, if the United States Secretary of Health and Human Services determines under subsection (c) of Section 274f-5 of Title 42 of the USC that participation in this clinical research is no longer warranted as a requirement for transplants, the individual is receiving the transplant under the standards and regulations under subsection (c) of Section 274f-5 of Title 42 of the USC, which requires the Secretary to, among other things, review the results of scientific research in conjunction with the Organ Procurement and Transplantation Network to determine whether the results warrant revision of the standards of quality.
- Removes specified penalties for donors included in 1) above and sperm donors, as specified, for the donation of blood or tissue by a person who knows that he or she has been found reactive for HIV, or for a person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person.
- Defines “organ,” for purposes of this bill, as a human kidney, liver, heart, lung, pancreas, or intestine (including the esophagus, stomach, small or large intestine, or any portion of the gastrointestinal tract), or vascularized composite allograft, and associated blood vessels recovered from an organ donor during the recovery of such organ.
- Exempts from tissue bank licensure the collection, processing, storage, or distribution of any organ, as specified, within a single general acute care hospital, as defined, operating a Medicare-approved transplant program.
- Prohibits disciplinary action by the MBC against a licensee who performs organ transplants within the standard of care and in compliance with this bill.
- Provides that this bill is an urgency statute in order to provide for organ donations and transplants to occur at the earliest opportunity.
Background
On November 21, 2013, President Obama issued a statement that announced he signed the bipartisan-supported HOPE Act, which allowed for scientists to carry out research into organ donations from one person with HIV to another. As noted in the statement, such organ transplants were deemed illegal for decades. However, with growing effective treatments for HIV and by signing the HOPE Act, successful life-saving organ donations for people living with HIV could eventually be realized. On November 22, 2013, Donate Life California issued a statement applauding the President’s signing of the HOPE Act, stating that the change in policy had the potential to save 1,000 HIV-infected transplant patients each year, as well as shortening the list for uninfected people awaiting transplants.
A March 30, 2016, article in the Los Angeles Times announced the first organ transplantation from a deceased HIV-positive donor to two HIV-positive recipients, performed by surgeons at Johns Hopkins University Medical Center. Physicians involved with the transplantation believe that many HIV-infected donors are likely healthy enough to donate an organ without great risk to their health. Also noted in the article is the expectation that each year 500 to 600 HIV-positive people will die under circumstances that would make their organs available for transplant, which has the potential to make hundreds and potentially thousands of transplantable organs available each year to HIV-infected people with end-stage diseases of the kidneys, heart, liver, and lungs.
Currently there are four hospitals who have met the criteria to participate in HOPE Act transplant research: Johns Hopkins Hospital in Baltimore, MD (liver and kidney programs); Hahnemann University Hospital in Philadelphia, PA (liver and kidney programs); Mount Sinai Medical Center in New York, NY (liver and kidney programs); and UCSF Medical Center, San Francisco, CA (liver [deceased and living donor] and kidney [deceased donor] programs).
Comments
Author’s statement. According to the author, this bill will greatly improve the life expectancies of people living with HIV who need organ or tissue transplants by removing California’s prohibition on donating organs or tissue while HIV-positive. Under current state law, it is illegal for an HIV-positive person to donate organs or tissues under any circumstance. This existing law was enacted nearly 20 years ago at a time when very little was known about HIV and AIDS. Research made possible by the passage of the federal HOPE Act of 2013 found that organ donations from HIV-positive donors to HIV-positive recipients do not have a detrimental effect. Major advances in the treatment of HIV and AIDS mean that HIV-positive individuals are living longer, and like other older Americans, they too are developing medical conditions that require organ transplants. However, the number of individuals in need of organ transplants far exceeds the availability of healthy organs. Increasing the number of eligible organ and tissue donors for HIV-positive individuals will save lives.
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
AIDS Project Los Angeles (co-source)
Equality California (co-source)
Los Angeles LGBT Center (co-source)
Positive Women’s Network—USA (co-source)
Access Support Network of San Luis Obispo and Monterey Counties
AIDS Healthcare Foundation
American Civil Liberties Union of California
Familia: Trans Queer Liberation Movement
Health Officers Association of California
Lambda Legal
Law Foundation of Silicon Valley
San Francisco AIDS Foundation
Two individuals
OPPOSITION: (Verified 5/26/16)
None received
ARGUMENTS IN SUPPORT: The sponsors and other supporters argue that this bill will bring state law into conformity with federal law, ending a policy that was enacted at a time when very little was known about HIV and AIDS. Supporters argue that with advances in HIV understanding and treatment, HIV-positive individuals are living longer and developing medical conditions later in life for which organ transplants are the standard of care treatment. Supporters state that this bill will help alleviate waiting times on donor lists for all people awaiting organ transplants, and that studies have shown that transplants from one HIV-positive person to another do not have a detrimental effect nor negatively affect patient outcomes.
5/27/16 9:35:26
**** END ****
Date of Hearing: May 25, 2016
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
SBPCA Bill Id:SB 1408
Author:(Allen) – As Amended Ver:May 23, 2016
SENATE VOTE: 34-0
SUBJECT: Organ donation.
SUMMARY: Allows for the transplantation of organs into the body of a person when the donor of the organ has human immunodeficiency virus (HIV). Specifically, this bill:
- Deletes the prohibition in existing law on the transplantation of tissue from a donor with HIV and instead permits such transplantation if the physician and surgeon performing the transplantation has ensured that the organ from an individual who has been found reactive to HIV may be transplanted only into an individual who satisfies both of the following:
- The individual has been found reactive for HIV before receiving the organ; and,
- The individual is either participating in clinical research approved by an institutional review board (IRB) pursuant to federal requirements, or if the United States Secretary of Health and Human Services (HHS) determines that participation in this clinical research is no longer warranted as a requirement for transplants, as specified.
- The individual has been found reactive for HIV before receiving the organ; and,
- Exempts the donation of organs from HIV positive individuals from specified criminal penalties.
- Defines "organ," for purposes of this bill, as a human kidney, liver, heart, lung, pancreas, or intestine (including the esophagus, stomach, small or large intestine, or any portion of the gastrointestinal tract), or vascularized composite allograft, and associated blood vessels recovered from an organ donor during the recovery of such organ.
- Provides that the Medical Board of California (MBC) will not take disciplinary action against a licensee who performs organ transplants in compliance with this bill.
EXISTING STATE LAW:
- Makes it a felony punishable by imprisonment of two, four, or six years for any person who knows that he or she has acquired immonodeficiency syndrome (AIDS) and donates blood, tissue, or semen to any medical center.
- Provides that no tissues be transferred into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive by laboratory tests for evidence of infection with HIV, agents of viral hepatitis (HBV and HCV), and syphilis.
- Allows the Department of Public Health (DPH) to adopt regulations requiring additional screening tests of donors of tissues when, in the opinion of DPH, the action is necessary for the protection of the public, donors, or recipients.
- Allows a recipient of sperm to consent to the use of sperm in assisted reproductive technologies if the sperm donor is found reactive for HBV, HCV, syphilis, HIV, or human T-lymphotropic (HTLV) if the sperm donor is the spouse of, partner of, or designated donor for that recipient. (The HTLV family of viruses are a group of human retroviruses that are known to cause a type of cancer called adult T-cell leukemia/lymphoma).
- Provides for an exception to the ban on transplantation of tissue from a donor who has not been screened or tested, with the exception of HIV and HTLV, or has been found reactive for the infection diseases listed in 2) above, or for which DPH has, by regulation, required additional screening tests, if both of the following conditions are satisfied:
- The physician performing the transplantation has determined any one or more of the following:
- Without the transplant the intended recipient will most likely die during the period of time necessary to obtain other tissue or to conduct the required tests;
- The intended recipient already is diagnosed with the infectious disease for which the donor tested positive; or,
- The symptoms from the infectious disease for which the donor has tested positive will most likely not appear during the intended recipient's likely lifespan after transplantation with the tissue or may be treated prophylactically if they do appear; and,
- Consent for the use of the tissue has been obtained from the recipient, if possible, or if not possible, from a member of the recipient's family, or the recipient's legal guardian.
- The physician performing the transplantation has determined any one or more of the following:
- Establishes the Medical Practice Act which gives the MBC the authority to license and regulate the practice of medicine.
EXISTING FEDERAL LAW establishes the HIV Organ Policy Equity (HOPE) Act which allows for research into transplanting organs from HIV-positive donors into HIV-positive recipients.
FISCAL EFFECT: None.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author this bill would greatly improve the life expectancies of people living with HIV who need organ transplants by removing California’s prohibition on donating organs while HIV-positive. The author notes that under current state law, it is illegal for an HIV-positive person to donate organs under any circumstance. The author points out this law was enacted nearly 20 years ago at a time when very little was known about HIV and AIDS, and that recent research made possible by the passage of the federal HOPE Act of 2013 found that organ donations from HIV-positive donors to HIV-positive recipients are safe. The author continues, major advances in the treatment of HIV and AIDS mean that HIV-positive individuals are living longer, and like other older Americans, they too are developing medical conditions that require organ transplants. However, the number of individuals in need of organ transplants far exceeds the availability of healthy organs and increasing the number of eligible donors for HIV-positive individuals will save lives. The author concludes that his request for expedited consideration of this bill is based on hearing from the University of California, San Francisco (UCSF) that two HIV-positive patients are in immediate need of the bill’s passage in order to have the surgeries performed.
- BACKGROUND.
- Ban on HIV-positive organ donations. According to an article published in September of 1987 in the journal Transfusion, an estimated 12,000 people in the United States contracted HIV from blood transfusions between 1978 and 1984, leaving the public fearful. In response, the U.S. passed a ban on organ collection from HIV-positive donors in 1988. However, by the late 1990s screening procedures for HIV had become accurate enough to eliminate this worry, and simultaneously, the development of effective antiretroviral drugs meant that HIV-infected people could expect to live to a relatively old age, and also develop the disorders that come with advancing age.
- Research on HIV-positive organ transplantation. In 1999 UCSF transplant surgeon, Dr. Peter Stock received a $3 million grant from the state of California for a pilot study transplanting uninfected livers and kidneys into HIV-positive recipients. The 37 patients appeared to do well overall and were only slightly more likely to reject organs than HIV-negative recipients were. In 2004, Dr. Stock and his colleagues published an article in the New England Journal of Medicine, "Outcomes of Kidney Transplantation in HIV-Infected Recipients." The article discussed the results of another trial in which 150 patients underwent kidney transplants between November 2003 and June 2009. According to the article, the trial showed that kidney transplantation appears to be a feasible therapy in carefully selected HIV-infected patients.
In 2008, a doctor in South Africa who followed Dr. Stock's work, Elmi Muller, transplanted two HIV-positive patients with kidneys from a single HIV-positive donor, and shortly thereafter a young man and his mother who had been turned down for dialysis. At that time in South Africa, patients with HIV could not access dialysis treatments, resulting in certain death. After much controversy Dr. Muller's work was allowed to proceed and in 2010 she published her first round of results showing that her patients thrived two years after the surgery.
A March 30, 2016, article in the Los Angeles Times announced the first organ transplantation from a deceased HIV-positive donor to two HIV-positive recipients in the US, performed by surgeons at Johns Hopkins University Medical Center in Baltimore Maryland. The surgeons who performed the transplants at Johns Hopkins conducted research, published in The American Journal of Transplantation in 2011 that each year 500 to 600 HIV-positive people will die under circumstances that would make their organs available for transplant, which has the potential to save about 1,000 lives each year. - Federal HOPE Act. On November 21, 2013, President Obama signed into law the HOPE Act, which allowed for scientists to carry out research into organ donations from one person with HIV to another. On November 21, 2015, the Secretary of HHS finalized the Organ Procurement and Transplantation Network (OPTN) standards of quality for the recovery and transplantation of organs from HIV-positive donors as required by the HOPE Act. The Secretary also developed and published criteria for research relating to transplantation of organs from donors infected with HIV into individuals who are infected with HIV, allowing the HOPE Act to take effect. The research criteria specifies that organs from individuals infected with HIV may be transplanted only into individuals who were infected with HIV before receiving such organs and are participating in clinical research approved by an IRB.
An IRB is a committee that has been formally designated to approve, monitor, and review biomedical and behavioral research involving humans conducted under the auspices of the institution with which it is affiliated. IRBs are regulated by the federal Office for Human Research Protection, and are required to have at least five members, including at least one member who is not otherwise affiliated with the institution. IRBs have the authority to approve, require modifications in, or disapprove all research activities under its review.
Currently there are four hospitals who have met the criteria to participate in HOPE Act transplant research: Johns Hopkins Hospital in Baltimore, Maryland (liver and kidney programs), Hahnemann University Hospital in Philadelphia, Pennsylvania (liver and kidney programs), Mount Sinai Medical Center in New York, New York (liver and kidney programs), and UCSF Medical Center, San Francisco, California (liver {deceased and living donor} and kidney {deceased donor} programs). - Transplantation in California. California law makes it a felony to donate blood, organs or other tissue, or semen by a person with AIDS. With the passage of the federal HOPE Act, UCSF is the only transplant program on the west coast that is qualified to participate; however current state law prohibits and penalizes such transplants. According to UCSF, two HIV-positive patients are in dire need of transplants and would benefit from the speedy passage of this bill. One patient with liver failure and cancer has a living donor ready and waiting. There are an additional 65 HIV-positive patients waiting for kidney or liver transplants at UCSF who would benefit if the HOPE Act could be implemented in California.
- Other States. Sixteen other states and one territory have laws prohibiting HIV-positive organ donations and transplantation: Delaware, Florida, Georgia, Idaho, Illinois, Kansas, Kentucky, Michigan, Minnesota, Missouri, North Carolina, South Carolina, South Dakota, Tennessee, Virginia, and the U.S. Virgin Islands, although Michigan, Minnesota, Missouri, and Virginia have exceptions for medical research.
- Who gets a transplant? OPTN allocation policies must, among other factors, be based on sound medical judgment, seek to achieve the best use of donated organs, and shall not be based on a candidate’s place of residence or listing except to the extent required to satisfy other factors. For liver disease, the Model for End-Stage Liver Disease (MELD) is a scoring system used to measure illness severity in liver transplant candidates. The system is used in the allocation of livers to adults and was established in February 2002. The MELD system calculates a score based on the clinical severity of illness that predicts the risk of death within three months on the waiting list. Livers are allocated to waitlisted patients with chronic liver disease based upon this score. The sicker the patient, the higher the score, and the more likely to receive a transplant. However, according to Dr. Stock, patients with HIV do not have the same survival on the wait list, they deteriorate at a significantly higher rate and therefore the MELD scoring system does not serve them well.
- Ban on HIV-positive organ donations. According to an article published in September of 1987 in the journal Transfusion, an estimated 12,000 people in the United States contracted HIV from blood transfusions between 1978 and 1984, leaving the public fearful. In response, the U.S. passed a ban on organ collection from HIV-positive donors in 1988. However, by the late 1990s screening procedures for HIV had become accurate enough to eliminate this worry, and simultaneously, the development of effective antiretroviral drugs meant that HIV-infected people could expect to live to a relatively old age, and also develop the disorders that come with advancing age.
According to OPTN there are currently 123,288 people in the U.S. waiting for a life-saving organ transplant, and every 10 minutes another person is added to that list. Each day an average of 22 patients die waiting for an organ. According to the United Network for Organ Sharing, approximately 23,000 Californians are on the waiting list for an organ transplant. Of the close to 31,000 organ transplants performed annually in the U.S., those involving organs from HIV-infected donors will remain a small minority. Experts at Johns Hopkins estimate that each year, 500 to 600 HIV-positive people will die under circumstances that would make their organs available for transplant.
- SUPPORT. AIDS Project Los Angeles, Equality California, Los Angeles LGBT Center, and the Positive Women's Network are the cosponsors of this bill and note that permitting HIV-positive individuals to donate their organs and tissue to HIV-positive patients in dire need has the potential to save the lives of hundreds of HIV-positive patients each year, as well as shortening the waiting list for all individuals awaiting transplants.
The University of California (UC) supports this bill stating UCSF is qualified and ready to proceed with life-saving transplants using HIV-positive donors, but cannot do so unless California's ban is lifted. UC notes that more than 60 UCSF patients who are HIV-positive are waiting for transplants that could ensure they live longer, healthier lives. - PREVIOUS LEGISLATION. AB 2356 (Skinner), Chapter 699, Statutes of 2012, permits the recipient of sperm donated by her sexually intimate partner for reproductive use to waive a second or repeat testing of that donor for HIV, agents of viral hepatitis, syphilis, and HTLV, if the recipient is informed of existing donor testing requirements and signs a written waiver. Exempts physicians or tissue banks that provide insemination or assisted reproductive technology services from liability and disciplinary actions, as specified.
- SUGGESTED AMENDMENT. As currently drafted this bill clarifies that the MBC will not take disciplinary action against a physician or surgeon who transplants an organ from an HIV-positive donor into an HIV-positive patient. In order to clarify that physicians and surgeons performing such transplants are following required standards of care this bill should be amended as follows:
(b) Subdivision (a) shall not apply to an organ transplant performed within the standard of care and in compliance with subdivision (d) of Section 1644.5 of the Health and Safety Code.
REGISTERED SUPPORT / OPPOSITION:
Support
AIDS Project Los Angeles (cosponsor)
Equality California (cosponsor)
Los Angeles LGBT Center (cosponsor)
Positive Women's Network (cosponsor)
Attorney General Kamala D. Harris
AIDS Healthcare Foundation
Donate Life California
Donor Network West
Lifesharing
OneLegacy
Sierra Donor Services
University of California
Opposition
None on file.
Analysis Prepared by: Lara Flynn / HEALTH / (916) 319-2097
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 1408 |
THIRD READING
Bill No: SB 1408
Amended: 5/4/16
SENATE HEALTH COMMITTEE: 8-0, 4/27/16
AYES: Hernandez, Nguyen, Mitchell, Monning, Nielsen, Pan, Roth, Wolk
NO VOTE RECORDED: Hall
SOURCE: AIDS Project Los Angeles
Equality California
Los Angeles LGBT Center
Positive Women’s Network—USA
DIGEST: This bill allows for the transplantation of any tissues into the body of a person, as specified, when the donor of the tissues is found reactive for human immunodeficiency virus (HIV), and removes penalties for tissue donors who are found reactive to HIV, as specified.
Existing law:
- Prohibits the transfer of any tissues, as defined, into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive for evidence of infection with HIV, agents of viral hepatitis (HBV and HCV), human T lymphotropic virus (HTLV), and syphilis, except as provided.
- Authorizes the transplantation of tissue from a donor who has not been tested for specified infectious diseases or, with the exception of HIV and HTLV, has been found reactive, if specified conditions are satisfied, including obtaining consent from an intended recipient or the recipient’s family. Defines “family” as a spouse, adult son or daughter, either parent, adult brother or sister, or grandparent.
This bill:
- Allows for the transplantation of any tissues into the body of a person who is found to be reactive for HIV when the donor of the tissues is also found reactive for HIV and both of the following conditions are satisfied:
- The individual receiving the tissue has been found reactive for HIV before receiving the tissue.
- The individual receiving the tissue is either participating in clinical research approved by an institutional review board under the criteria, standards, and regulations described in subsections (a) and (b) of Section 274f-5 of Title 42 of the United States Code (USC), or, if the U.S. Secretary of Health and Human Services determines under subsection (c) of Section 274f-5 of Title 42 of the USC that participation in this clinical research is no longer warranted as a requirement for transplants, the individual is receiving the transplant under the standards and regulations under subsection (c) of Section 274f-5 of Title 42 of the USC.
- Removes specified penalties for the donation of blood, body organs, or other tissues by a person who knows that he or she has been found reactive for HIV, or for a person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, for sperm donors, as specified, and donors included in 1) above.
Background
On November 21, 2013, President Obama issued a statement that announced he signed the bipartisan-supported HIV Organ Policy Equity (HOPE) Act, which allowed for scientists to carry out research into organ donations from one person with HIV to another. As noted in the statement, such organ transplants were deemed illegal for decades. However, with growing effective treatments for HIV and by signing the HOPE Act, successful life-saving organ donations for people living with HIV could eventually be realized. On November 22, 2013, Donate Life California issued a statement applauding the President’s signing of the HOPE Act, stating that the change in policy had the potential to save 1,000 HIV-infected transplant patients each year, as well as shortening the list for uninfected people awaiting transplants.
A March 30, 2016, article in the Los Angeles Times announced the first organ transplantation from a deceased HIV-positive donor to two HIV-positive recipients, performed by surgeons at Johns Hopkins University Medical Center. Physicians involved with the transplantation believe that many HIV-infected donors are likely healthy enough to donate an organ without great risk to their health. Also noted in the article is the expectation that each year 500 to 600 HIV-positive people will die under circumstances that would make their organs available for transplant, which has the potential to make hundreds and potentially thousands of transplantable organs available each year to HIV-infected people with end-stage diseases of the kidneys, heart, liver, and lungs.
Comments
Author’s statement. According to the author, this bill will greatly improve the life expectancies of people living with HIV who need organ or tissue transplants by removing California’s prohibition on donating organs or tissue while HIV-positive. Under current state law, it is illegal for an HIV-positive person to donate organs or tissues under any circumstance. This existing law was enacted nearly 20 years ago at a time when very little was known about HIV and AIDS. Research made possible by the passage of the federal HOPE Act of 2013 found that organ donations from HIV-positive donors to HIV-positive recipients do not have a detrimental effect. Major advances in the treatment of HIV and AIDS mean that HIV-positive individuals are living longer, and like other older Americans, they too are developing medical conditions that require organ transplants. However, the number of individuals in need of organ transplants far exceeds the availability of healthy organs. Increasing the number of eligible organ and tissue donors for HIV-positive individuals will save lives.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
AIDS Project Los Angeles (co-source)
Equality California (co-source)
Los Angeles LGBT Center (co-source)
Positive Women’s Network—USA (co-source)
Access Support Network of San Luis Obispo and Monterey Counties
AIDS Healthcare Foundation
American Civil Liberties Union of California
Familia: Trans Queer Liberation Movement
Health Officers Association of California
Lambda Legal
Law Foundation of Silicon Valley
San Francisco AIDS Foundation
Two individuals
None received
ARGUMENTS IN SUPPORT: The sponsors and other supporters argue that this bill will bring state law into conformity with federal law, ending a policy that was enacted at a time when very little was known about HIV and AIDS. Supporters argue that with advances in HIV understanding and treatment, HIV-positive individuals are living longer and developing medical conditions later in life for which organ transplants are the standard of care treatment. Supporters state that this bill will help alleviate waiting times on donor lists for all people awaiting organ transplants, and that studies have shown that transplants from one HIV-positive person to another do not have a detrimental effect nor negatively affect patient outcomes.
Prepared by: Reyes Diaz/ HEALTH /
5/4/16 15:04:26
**** END ****
SENATE COMMITTEE ON HEALTH
Senator Ed Hernandez, O.D., Chair
BILL NO: SB 1408
AUTHOR: | Allen | ||
VERSION: | April 18, 2016 | ||
HEARING DATE: | April 27, 2016 | ||
CONSULTANT: | Reyes Diaz | ||
SUBJECT: Tissue donation
SUMMARY:
Allows for the transplantation of any tissues into the body of a person when the donor of the tissues is found reactive for human immunodeficiency virus (HIV), as specified, and removes penalties for tissue donors who are reactive to HIV, as specified.
Existing law:
- Prohibits the transfer of any tissues, as defined, into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive for evidence of infection with HIV, agents of viral hepatitis (HBV and HCV), human T lymphotropic virus (HTLV), and syphilis, except as provided.
- Authorizes the transplantation of tissue from a donor who has not been tested for specified infectious diseases or, with the exception of HIV and HTLV, has been found reactive, if specified conditions are satisfied, including obtaining consent from an intended recipient or the recipient’s family. Defines “family” as a spouse, adult son or daughter, either parent, adult brother or sister, or grandparent.
This bill:
- Allows for the transplantation of any tissues into the body of a person when the donor of the tissues is found reactive for HIV, if both of the following conditions are satisfied:
- The physician and surgeon performing the transplantation has determined any one or more of the following: i) without the transplantation, the intended recipient will most likely die during the period of time necessary to obtain other tissue or to conduct required tests; ii) the intended recipient already is diagnosed with the infectious disease for which the donor has tested positive; or iii) the symptoms from the infectious disease for which the donor has tested positive will most likely not appear during the intended recipient’s likely lifespan after transplantation with the tissue or may be treated prophylactically if they do appear; and,
- Consent for the use of the tissue has been obtained from the recipient, if possible, or if not possible, from a member of the recipient’s family or the recipient’s legal guardian.
- Removes specified penalties for the donation of blood, body organs, or other tissues by a person who knows that he or she has tested reactive to HIV, or for a person afflicted with any contagious, infectious, or communicable disease who willfully exposes himself or herself to another person, for sperm donors, as specified, and donors included in 1) above.
FISCAL EFFECT:
This bill is keyed non-fiscal.
COMMENTS:
- Author’s statement. According to the author, this bill would greatly improve the life expectancies of people living with HIV who need organ or tissue transplants by removing California’s prohibition on donating organs or tissue while HIV-positive. Under current state law, it is illegal for an HIV-positive person to donate organs or tissues under any circumstance. This existing law was enacted nearly 20 years ago at a time when very little was known about HIV and AIDS. Research made possible by the passage of the federal HIV Organ Policy Equity (HOPE) Act of 2013 found that organ donations from HIV-positive donors to HIV-positive recipients do not have a detrimental effect. Major advances in the treatment of HIV and AIDS mean that HIV-positive individuals are living longer, and like other older Americans, they too are developing medical conditions that require organ transplants. However, the number of individuals in need of organ transplants far exceeds the availability of healthy organs. Increasing the number of eligible organ and tissue donors for HIV-positive individuals will save lives.
- Background. On November 21, 2013, President Obama issued a statement that announced he signed the bipartisan-supported HOPE Act, which allowed for scientists to carry out research into organ donations from one person with HIV to another. As noted in the statement, such organ transplants were deemed illegal for decades. However, with growing effective treatments for HIV and by signing the HOPE Act, successful life-saving organ donations for people living with HIV could eventually be realized. On November 22, 2013, Donate Life California issued a statement applauding the President’s signing of the HOPE Act, stating that the change in policy had the potential to save 1,000 HIV-infected transplant patients each year, as well as shortening the list for uninfected people awaiting transplants.
A March 30, 2016, article in the Los Angeles Times announced the first organ transplantation from a deceased HIV-positive donor to two HIV-positive recipients, performed by surgeons at Johns Hopkins University Medical Center. Physicians involved with the transplantation believe that many HIV-infected donors are likely healthy enough to donate an organ without great risk to their health. Also noted in the article is the expectation that each year 500 to 600 HIV-positive people will die under circumstances that would make their organs available for transplant, which has the potential to make hundreds and potentially thousands of transplantable organs available each year to HIV-infected people with end-stage diseases of the kidneys, heart, liver, and lungs.
- Support. The sponsors and other supporters argue that this bill will bring state law into conformity with federal law, ending a policy that was enacted at a time when very little was known about HIV and AIDS. Supporters argue that with advances in HIV understanding and treatment, HIV-positive individuals are living longer and developing medical conditions later in life for which organ transplants are the standard of care treatment. Supporters state that this bill will help alleviate waiting times on donor lists for all people awaiting organ transplants, and that studies have shown that transplants from one HIV-positive person to another do not have a detrimental effect nor negatively affect patient outcomes.
- Technical amendment. On page 6, line 6, strike out “of”
SUPPORT AND OPPOSITION:
Support: AIDS Project Los Angeles (cosponsor)
Equality California (cosponsor)
Los Angeles LGBT Center (cosponsor)
Positive Women’s Network—USA (cosponsor)
Access Support Network of San Luis Obispo and Monterey Counties
AIDS Healthcare Foundation
American Civil Liberties Union of California
Familia: Trans Queer Liberation Movement
Health Officers Association of California
Lambda Legal
Law Foundation of Silicon Valley
San Francisco AIDS Foundation
Two individuals
Oppose: None received
-- END --
Bill Author
Bill Co-Author(s):